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Summary 
 
One of the aims of direct observed therapy strategy implemented by the World Health 
Organization was to prevent the development of drug resistant tuberculosis. However, in recent 
years a dramatic increase and spread in multidrug resistant tuberculosis has been observed. In 
this study, a molecular epidemiological approach was used to understand and rapidly detect drug 
resistance in high incidence tuberculosis communities of the Western Cape, South Africa. 
Previous studies showed that, drug resistant tuberculosis occurs as a result of spontaneous 
mutations in particular genes. Using molecular techniques, we developed an algorithm to rapidly 
detect isoniazid, rifampicin and ethambutol drug resistance in tuberculosis patients from a short 
term mini culture. Rapid detection of drug resistance is important to prevent future transmission 
events. In addition, accurate ethambutol resistance testing is of particular importance, since 
treatment of patients infected with multidrug resistant strains with second line anti-tuberculosis 
drugs depend on the ethambutol test results. In a comprehensive study, we found that the 
algorithm performs well when compared to the traditional culture method currently used by the 
routine laboratories. However, the results showed that more then 90 % of ethambutol resistance 
is missed by the routine laboratories. This has important implications for the tuberculosis control 
program, since patients infected with the drug resistant strain may be on inappropriate treatment. 
 
In this study, we found that certain strains have a selective advantage to become drug resistant 
and transmit and this implies that they are more virulent and fit than other strains. This 
observation has also been made for strains within the same genotype family. The more 
transmissible drug resistant strains cause large drug resistant outbreaks.  
 
 iv
This study highlights the complexity of the drug resistant epidemic, and confirms that it is a 
major problem in local communities. Application of molecular methods has provided us with 
tools to study how resistance might develop. We have demonstrated how we made use of a 
newly developed method to detect a multidrug resistant outbreak in the study community. The 
applications of transcriptomics identified several genes that might play a role in isoniazid 
resistance. Using this data a model was proposed whereby isoniazid resistant strains can 
compensate for the toxic effect of the drug. Application of comparative genomics by whole 
genome sequencing will be used to assist us in the further understanding of the mechanisms of 
drug resistance. 
 
This study also conclude that we should continue in our attempts to develop faster diagnostics 
for both first and second line drugs and that we must not loose site that all of this research must 
in the end benefit the patients. 
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OPSOMMING 
 
Een van die doelstellings van die direkte observasie terapie strategië van die Wêreld 
Gesondheidsorganisasie is die voorkoming van middelweerstandigheid in tuberkulose. In die 
laaste paar jaar is daar egter ‘n dramatise toename en verspreiding van middelweerstandige 
stamme van Mycobacterium tuberculosis waargeneem. In hierdie studie is daar van ‘n 
molekulêre epidemiologiese aanslag gebruik gemaak om die meganismes van 
middelweerstandigheid verder te verstaan en om tegnieke te ontwikkel om middel weerstandige 
tuberkulose ten volle te diagnoseer. Deur gebruik te maak van hierdie kennis, is ‘n algoritme 
ontwikkel om isoniasied, rifampisien en ethambutol weerstandigheid direk van speeksel vas te 
stel. Akurate toetsing vir ethambutol weerstandbiedendheid is veral noodsaaklik, aangesien 
verdere behandeling van pasiente wat geinfekteer is met n weerstandige organisme van tweede 
linie anti-tuberkulose middels afhanklik is. In ‘n omvattende studie is gevind dat die algoritme 
goed vergelyk met die tradisionele kultuurmetode, wat tans in roetine laboratoriums gebruik 
word. Bevindings toon dat meer as 90 % van ethambutol weerstandigheid nie deur die roetine 
laboratoriums opgespoor word nie. Hierdie bevindings het baie belangrike implikasies vir die 
Tuberkulose Beheer Program, want dit beteken dat pasiente war reeds met middel weerstandige 
organismes geinfekteer is, dan op verkeerde behandeling is.  
 
Sekere M. tuberculosis stamme het‘n selektiewe voordeel om weerstandig te word en dan in die 
gemeenskap te versprei. Dit impliseer dat hulle meer virulent en fiks is as ander stamme. Hierdie 
waarnemning is ook gemaak vir sekere stamme binne dieselfde genetipiese stamboom.  
Transkripsiestudies het bygedra tot die identifisering van bykomende gene wat ‘n rol mag speel 
in isoniasied weerstandigheid. Met behulp van hierdie data is ’n model voorstel wat wys hoe ’n 
isoniasied weerstandige stam kan kompenseer vir die toksiese uitwerking van die anti-
 vi
tuberkulose middel. Volledige genoom volgorde bepaling kan gebruik word ten einde verdere 
meganismes van middel weerstandheid en virulensie verder te kan bestudeer. 
 
Die studie belemtoon die kompleksiteit van die middelweerstandige epidemie en bevestig verder 
dat dit n ernstige probleem in plaaslike gemeenskappe is. Die gebruik van molekulêre tegnieke 
het ons in staat gestel om meganismes vir die ontstaan van weerstandigheid te bestudeer. Verder 
is nuut ontwikkelde metodes gebruik om ’n uitbraak van middel weerstandige tuberkulose binne 
die studiegemeenskap te identifiseer. Die studie sluit af met n voorstel dat daar deurgaans 
gewerk moet word aan die ontwikkeling van vinniger diagnostiese metodes om middel 
weerstandige tuberkulose vir eerste en tweede linie middels te kan identifiseer. Navorsers 
behoort in ag te neem dat dit uiteindelik die pasiënt is wat by al hierdie stuidies moet baat. 
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Introduction 
 
Tuberculosis (TB) is caused by the bacillus Mycobacterium tuberculosis (M. tuberculosis) and has 
been part of the human population since antiquity (11). Soon after the first antibiotic for TB 
treatment was administered in 1948, the general thought was that the TB epidemic was under 
control and can be written up in history. However, more then 55 years later, the TB epidemic 
remains a threat with sub-Saharan Africa having the highest prevalence of TB in the world (1). In 
the latest TB surveillance data for 2005, South Africa ranked 7th in the world with an prevalence 
rate for all forms of TB of 600/100 000 (19). The Western Cape Province of South Africa was found 
to have the highest TB prevalence for 2006 with a TB prevalence rate for all forms of TB of 
998/100 000 (8). 
 
Over the past decades, the tuberculosis bacilli became resistant to various anti-TB drugs, making 
infection control increasingly difficult. Drug resistant TB occurs through selection where in a 
selective environment (in the presence of a drug), the sensitive bacterial population is killed and the 
resistant mutant is allowed to grow, and this is called acquired resistance. This form of resistance 
has resulted in the emergence of multidrug resistant TB (MDR-TB), defined as resistance to 
Isoniazid (INH) and Rifampicin (RIF), and more recently, extensively drug resistant TB (XDR-TB). 
XDR-TB is defined as resistance to INH, RIF, plus any fluoroquinolone and at least one of the three 
injectable second–line drugs (amikacin, kanamycin and capreomycin) (9). According to a weekly 
report published in 2006 by Center of Disease Control (CDC), it was found that during 2000-2004, 
Chapter 1 
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20 % of the TB strains collected world wide were MDR and one tenth of those strains were XDR-
TB strains (1). South Africa was listed in the third world report on drug surveillance as one of the 
hot spots for MDR-TB, where more than 6000 new MDR-TB cases are detected each year (18). 
However, the extent of XDR-TB in South Africa is not known since second line testing was not 
performed routinely. Thus, XDR-TB could have been present in South Africa long before the first 
reports of XDR-TB hit Tugela Ferry (1). Currently there are no new anti-TB drugs available to treat 
patients. Most of the new promising TB drugs are under development and are still in the preclinical 
stage. It is predicted that the earliest new drug will be available in 2010 (1). This emerging drug 
resistant problem is of great concern for the control of TB therefore, there is a need to further 
understand the mechanisms of drug resistance and to use the knowledge to develop fast and accurate 
detection methods that can rapidly detect drug resistance.  
 
Routine drug susceptibility testing depends on a positive culture for diagnosis after which a drug 
susceptibility test is performed which usually takes 3-6 weeks (17). The slow diagnosis and in some 
cases inaccurate or false negative phenotypic results (15), may be a major contributor to the current 
drug resistant epidemic. During the last decade molecular methods such as, PCR based technologies 
and IS6110 restriction fragment length polymorphism (IS6110-RFLP) for example, have 
increasingly been applied to control drug resistant TB. IS6110-RFLP analysis for instance, can be 
used to distinguish between reactivation and reinfection, while the use of mutational analysis may 
shed light on primary versus acquired drug resistance. 
 
The combination of IS6110-RFLP and drug resistant genotyping can also be used as a powerful tool 
in the investigation and identification of outbreaks, as well as the transmission dynamics of outbreak 
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strains. It has also been found that certain strain families are more prominent in certain geographical 
settings and are often responsible for a large proportion of the disease episodes that occur within 
that region, making them more transmissible than other strains in the same geographical setting 
(13,14,16). An example of such a strain family is the Beijing which have been the focus of most 
MDR-TB outbreaks reported to date (6,7,10).  
 
Molecular biology of TB underwent revolutionary changes over the past decades (4). With the 
availability of the complete M. tuberculosis genome data (3), a new foundation has been laid that 
will serve as a powerful framework in the understanding of the molecular genetics of drug resistant 
strains. Also with the application of functional genomic techniques, such as transcriptomics or 
proteomics, the biology of M. tuberculosis can be explored and the response can be measured by 
using techniques such as microarray analysis, two-dimentional (2-D) gel2-D gel electrophoresis and 
subsequent quadrupole-time of flight (Q-TOF) analysis. The application of these technologies 
depends on the type of information that needs to be generated from the data set. The following are 
examples: 
 
• Comparative genomics: (5) 
• Gene regulation: (12) 
• Differential gene and protein expression: (2) 
The information gained can be used to understand the underlying mechanism that causes M. 
tuberculosis to develop drug resistance. More importantly, it can also be used in future studies for 
drug discovery, the development of new diagnostic markers, transmissibility and to study virulence. 
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In this study we hypothesize that understanding the mechanisms of drug resistance in M. 
tuberculosis may ultimately lead to the control of drug resistance. The general aim of this study is to 
use molecular techniques to study the molecular mechanisms of drug resistance in M. tuberculosis 
and to apply the knowledge gained to develop new diagnostic methods which can be applied in high 
incidence communities. 
 
This thesis was divided into the following themes which include: 
i. M. tuberculosis drug resistance review (Chapter 2) 
ii. molecular detection of drug resistance (Chapter 3 and 4) 
iii. molecular epidemiology (Chapter 5 and 6) and 
iv. differential gene expression (Chapter 7 and 8) 
 
Each chapter is structured according to the journal in which the article was published and if the 
results in a particular chapter have not been published yet, the specification prescribed for Journal of 
Clinical Microbiology has been used. 
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ABSTRACT 
Anti-tuberculosis drugs are a two-edged sword. While they destroy pathogenic M. tuberculosis 
they also select for drug resistant bacteria against which those drugs are then ineffective. Global 
surveillance has shown that drug resistant Tuberculosis is widespread and is now a threat to 
Tuberculosis control programs in many countries. Application of molecular methods during the 
last decade has greatly changed our understanding of drug resistance in Tuberculosis. 
Application of molecular epidemiological methods was also central to the description of 
outbreaks of drug resistance in Tuberculosis. This review describes recommendations for 
Tuberculosis treatment according to the WHO guidelines, the drug resistance problem in the 
world, mechanisms of resistance to first line and second line drugs and applications of molecular 
methods to detect resistance causing gene mutations. It is envisaged that molecular techniques 
may be important adjuncts to traditional culture based procedures to rapidly screen for drug 
resistance. Prospective analysis and intervention to prevent transmission may be particularly 
helpful in areas with ongoing transmission of drug resistant strains as recent mathematical 
modeling indicate that the burden of MDR-TB cannot be contained in the absence of specific 
efforts to limit transmission.  
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1. INTRODUCTION 
1.1 Drug Resistance and Global Surveillance: History 
Shortly after the first anti-tuberculosis (TB) drugs were introduced, streptomycin (STR), para-
aminosalicylic acid (PAS), isoniazid (INH)) resistance to these drugs was observed in clinical 
isolates of Mycobacterium tuberculosis (Crofton and Mitchison, 1948). This lead to the need to 
measure resistance accurately and easily. The Institute Pasteur introduced the critical proportion 
method in 1961 for drug susceptibility testing in TB and this method became the standard 
method of use (Espinal, 2003). Studies on drug resistance in various countries in the 1960’s 
showed that developing countries had a much higher incidence of drug resistance than developed 
countries (Espinal, 2003). By the end of the 1960’s rifampicin (RIF) was introduced and with the 
use of combination therapy, there was a decline in drug resistant and drug susceptible TB in 
developed countries. This led to a decline in funding and interest in TB control programs. As a 
result, no concrete monitoring of drug resistance was carried out for the following 20 years 
(Espinal, 2003). The arrival of HIV/AIDS in the 1980’s resulted in an increase in transmission of 
TB associated with outbreaks of multi-drug-resistant TB (MDR-TB) (Edlin et al., 1992; Fischl et 
al., 1992) i.e. resistant to INH and RIF. In the early 1990’s drug resistance surveillance was 
resumed in developed countries, but the true incidence remained unclear in the developing world 
(Cohn et al., 1997).   
 
1.2 The WHO/IUATLD Global Project on Drug-Resistance Surveillance 
In 1994 the Global Project on Drug-Resistance Surveillance was initiated to monitor the trends 
of resistance. The first report was published in 1997 and contained data from 35 geographical 
settings for the period 1994-1996 (World Health Organization, 1997; Pablos-Mendez et al., 
1998). The report showed that drug resistance was present globally, and that MDR-TB ranged 
from 0 % to 14 % in new cases (median: 1.4 %) and 0 % to 54 % in previously treated cases 
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(median: 13 %). A second report for the period 1996-1999, followed in 2000 and included 
surveillance data from 58 geographical sites (Espinal, 2003; World Health Organization, 2000). 
This report confirmed that drug resistant TB was a sufficient problem since MDR-TB ranged 
from 0-16 % (median: 1 %) among new cases and from 0 % to 48% (median: 9 %) in previously 
treated cases. The recently published third report has data on 77 geographical sites, collected 
between 1999 and 2002, representing 20 % of the global total of new smear-positive TB cases 
(World Health Organization, 2003). Eight countries did not report any MDR-TB amongst new 
cases, while the highest incidence of MDR-TB amongst new cases occurred in Kazakhstan and 
Israel (14 %). Significant increases in MDR-TB prevalence were seen in Estonia, Lithuania, 
Tomsk Oblast (Russian Federation) and Poland and significant decreasing trends in Hong Kong, 
Thailand and the USA. The highest prevalence of MDR-TB among previously treated cases was 
reported in Oman (58.3 %, 7/12) and Kazakhstan (56.4 %, 180/319). The annual incidence of 
MDR-TB in most Western and Central European Countries was estimated to be fewer than 10 
cases each. Alarmingly, it is estimated that the annual incidence of MDR-TB for 2 provinces in 
China (Henan and Hubei) is 1000 and for Kazakhstan and South Africa it is more than 3000. 
According to the report, the most effective means to prevent the emergence of drug resistance is 
by implementing the direct observed therapy strategy (DOTS) (World Health Organization, 
2003).   
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1.3 Current Recommendations for TB Treatment by WHO 
TB persists as a global public health problem and the main focus for the twentieth century is 
firstly to cure the individual patient and secondly to minimize the transmission of M. 
tuberculosis to other persons (World Health Organization, 2003; Blumberg et al., 2003). The 
ongoing TB problem has been due to the neglect of TB control by governments, inadequate 
access and infrastructure, poor patient adherence to medication, poor management of TB control 
programs, poverty, population growth and migration, and a significant rise in the number of TB 
cases in HIV infected individuals. Treatment of patients with TB is most successful within a 
comprehensive framework based upon the following five key components: 
• Government commitment 
• Case detection by sputum smear microscopy 
• Standardized treatment regimen of six to eight months  
• A regular, uninterrupted supply of all essential anti-TB drugs 
• A standard recording and reporting system 
These five key elements are the recommended approach by the World Health Organization 
(WHO) to TB control and are called the DOTS strategy (Walley, 1997). DOTS are an 
inexpensive strategy for the detection and treatment of TB. DOTS were implemented as part of 
an adherence strategy in which patients are observed to swallow each dose of anti-TB 
medication, until completion of the therapy. Monthly sputum specimens are taken until 2 
consecutive specimens are negative. Currently there are four recommended regimens for treating 
patients with TB infection by drug–susceptible organisms. Each regiment has an initial phase of 
2 months intensive phase followed by a choice of several options for the continuation phase of 
either 4 or 7 months. The recommended regimens together with the number of doses specified 
by the regimen are described in Table 1.   
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Table 1. Drug Regimen for Culture-Positive Pulmonary TB Caused by Drug-Susceptible Organisms 
Intensive Phase Continuation Phase 
Regimen Drugs Doses Regimen Drugs Doses 
INH/RIF 
    7d/wk for 126 doses (18 
wk) 
              or 
5d/wk for 90 doses (18 
wk) 
INH/RIF 2d/wk for 36 doses (18wk) 
1 INH,RIF,PZA, 
EMB 
7 d /wk for 56 doses 
(8wk)   
           or 
5 d/wk for 40 doses 
(8wk) 1 
INH/RPT 1 wk for 18 doses (18wk) 
INH/RIF 2d/ wk for 36 doses 2 INH, RIF PZA, 
EMB 
7 d/wk for 14 doses 
(2wks), then 
2 d/wk for 
12doses(6wks) 
            or 
5 d/wk for 10 doses 
(2wk), then 
2 d/wk for 12 doses 
(6 wk) 
2 INH/RPT 1 wk for 18 doses (18wk) 
3 INH, RIF PZA, EMB 
3d/wk for 24 doses 
(8wk) 3 INH/RIF 
3 wk for 54 doses 
(18wk) 
4 INH, RIF, EMB 
7 d/wk for 56 doses 
(8wk) 
             or 
5 d/wk for 40 doses 
(8 wk) 
4 INH/RIF 
7 d/wk for 217 doses 
(31 wk) 
              or 
2d/wk for 62 doses (31 
wk) 
Legend to Table 1. INH-isoniazid; RIF-rifampicin; RPT-rifapentine; PZA-pyrazinamide;  
Note: Streptomycin (STR) efficiency is equal to that of EMB and was use as an interchangeable drug with EMB in 
the initial phase of treatment.  Due to the increase of resistance the drug is rendered less useful.  Thus, STR is not 
recommended to be interchangeable with EMB unless the organism is known to be susceptible to the drug or the 
patient is from a community in which STR resistance is unlikely.  Extracted from Blumberg et al.(Blumberg et al., 
2003) 
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Since the introduction of the DOTS strategy in the early ‘90s by the WHO, considerable 
progress has been made in global TB control (Sterling et al., 2003). In 1997, the estimated 
average treatment success rate world wide was almost 80 %. However, less than 25 % of people 
who are sick with TB are treated through the DOTS strategy (Bastian et al., 2000) . A total of 
180 countries (including both developed and undeveloped countries) had adopted and 
implemented the DOTS strategy by the end of 2002 and 69 % of the global population was 
living in areas covered by the DOTS strategy (Blumberg et al., 2003). However, even though 
DOTS programs are in place, treatment success rates are very low in developed countries due to 
poor management of TB control programs and patient non-compliance (Lienhardt and Ogden, 
2004; Bastian et al., 2003) Furthermore, the effectiveness of DOTS is facing new challenges 
with respect to the spread and increase of MDR-TB and the co-epidemic of TB/HIV (World 
Health Organization, 2003). WHO and partners have addressed these new challenges and have 
developed a new strategy called DOTS-Plus for the treatment of MDR-TB and its co-epidemic 
TB/HIV.  The goal of DOTS-plus is to prevent further development and spread of MDR-TB and 
is a comprehensive management initiative built upon the DOTS strategy (Table 2). It is 
important to note that DOTS-Plus should only be implemented in areas were the DOTS strategy 
is in place as there can be no DOTS-plus without an effective DOTS program.   
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Table 2. DOTS Compared to DOTS-Plus Strategy 
DOTS DOTS-plus 
• DOTS prevent emergence of drug 
resistant TB and MDR-TB 
• DOTS-plus design to cure MDR-TB 
using second line drugs. 
• Make primarily use of 1st line drugs  
that are less expensive 
• Make use of 2nd line drugs that are  
more toxic and expensive, difficult to  
treat less effective to administrate 
and often poorly tolerated 
 DOTS-plus needed in areas where 
MDR-TB has emerged due to 
previous inadequate TB control 
 • DOTS-plus only recommended in 
settings where DOTS strategy is 
fully in place to prevent against the  
development of further drug 
resistance 
 
 
 
2. DRUG SUSCEPTIBILITY TESTING 
Drug susceptibility testing is carried out on sub-cultured bacteria after the initial positive culture 
is obtained for diagnosis. It usually takes 3-6 weeks to obtain the initial positive culture with an 
additional 3 weeks for susceptibility testing (reduced to about 15 days when using the BACTEC 
system) (Rastogi et al., 1989; Siddiqi et al., 1985; Snider, Jr. et al., 1981; Tarrand and Groschel, 
1985). Thus, susceptibility testing is time consuming and costly, and there are numerous 
problems associated with the standardization of tests and the stability of the drugs in different 
culture media (Martin-Casabona et al., 1997; Victor et al., 1997). The slow diagnosis of drug 
resistance may be a major contributor to the transmission of MDR-TB (Victor et al., 2002). The 
WHO recommended that drug susceptibility testing is done by the proportion method on 
Löwenstein-Jensen medium, but other media, such as Middlebrook 7H10, 7H11, 7H12 
(BACTEC460TB) and other methods, including the absolute concentration and resistance ratio 
methods, may also be used (World Health Organization, 2001). For the ratio method, serial 
dilutions are cultured on 2 control media (without the drug) and 2 test media (with two different 
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drug concentrations). The colonies on the different slants are counted after 21 and 40 days of 
growth. The proportion of resistant bacilli is calculated by comparing colony counts on drug free 
and drug containing media. For a resistant isolate the calculated proportion is higher and for a 
susceptible strain the calculated proportion is lower than the critical proportion (World Health 
Organization, 2001). 
 
 
3.  MOLECULAR MECHANISMS OF DRUG RESISTANCE 
In order to control the drug resistance epidemic it is necessary to gain insight into how M. 
tuberculosis develops drug resistance. This knowledge will help us to understand how to prevent 
the occurrence of drug resistance as well as identifying genes associated with drug resistance of 
new drugs. The development of clinical drug resistance in TB is summarized in Figure 1 and is 
classified as acquired resistance when drug resistant mutants are selected as a result of 
ineffective treatment or as primary resistance when a patient is infected with a resistant strain. 
Mutations in the genome of M. tuberculosis that can confer resistance to anti-TB drugs occur 
spontaneously with an estimated frequency of 3.5 x 10-6 for INH and 3.1 x 10-8 for RIF. Because 
the chromosomal loci responsible for resistance to various drugs are not linked, the risk of a 
double spontaneous mutation is extremely low: 9 x 10-14 for both INH and RIF (Dooley and 
Simone, 1994). MDR-TB defined as resistance to at least INH and RIF will thus occur mainly in 
circumstances where sequential drug resistance follows sustained treatment failure. Treatment 
can be divided into first line and second line drugs according to the WHO TB treatment regimen 
and the mechanisms of these will be discussed separately. 
 
  
16
 
Figure 1. Acquired Resistance Develops due to Natural Selection which is a Function of 
Ineffective Treatment and Non-Compliance 
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Few bacteria naturally 
resistant (mutations) 
INH = 3.5 x 10-6 
RIF = 3.1 x 10-8  
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Overgrowth of resistant 
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same host 
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3.1. FIRST LINE DRUGS 
Any drug used in the anti-TB regiment is supposed to have an effective sterilizing activity that is 
capable of shortening the duration of treatment.  Currently, a four-drug regiment is used 
consisting of INH, RIF, pyrazinamide (PZA) and ethambutol (EMB). Resistance to first line 
anti-TB drugs has been linked to mutations in at least 10 genes; katG, inhA, ahpC, kasA and ndh 
for INH resistance; rpoB for RIF resistance, embB for EMB resistance, pncA for PZA resistance 
and rpsL and rrs for STR resistance.   
 
 
 
3.1.1 Isoniazid 
3.1.1.1 KatG  
INH or isonicotinic acid hydrazide, was synthesized in the early 1900’s but its anti-TB action 
was first detected in 1951 (Heym et al., 1999; Slayden and Barry, III, 2000; Rattan et al., 1998). 
INH enters the cell as a prodrug that is activated by a catalase peroxidase encoded by katG. The 
peroxidase activity of the enzyme is necessary to activate INH to a toxic substance in the 
bacterial cell (Zhang et al., 1992). This toxic substance subsequently affects intracellular targets 
such as mycolic acid biosynthesis which are an important component of the cell wall. A lack of 
mycolic acid synthesis eventually results in loss of cellular integrity and the bacteria die (Barry, 
III et al., 1998). Middlebrook et al. initially demonstrated that a loss of catalase activity can 
result in INH resistance (Middlebrook, 1954). Subsequently genetic studies demonstrated that 
transformation of INH-resistant Mycobacterium smegmatis and M. tuberculosis strains with a 
functional katG gene restored INH susceptibility and that katG deletions give rise to INH 
resistance (Zhang et al., 1992; Zhang et al., 1993). However, mutations in this gene are more 
frequent than deletions in clinical isolates and these can lower the activity of the enzyme. Most 
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mutations are found between codons 138 and 328 with the most commonly observed gene 
alteration being at codon 315 of the katG gene (Slayden and Barry, III, 2000). The Ser315Thr 
substitution is estimated to occur in 30-60 % of INH resistant isolates (Ramaswamy and Musser, 
1998; Musser et al., 1996; Slayden and Barry, III, 2000). The katG 463 (CGG-CTG) (Arg-Leu) 
amino acid substitutions is the most common polymorphism found in the katG gene and is not 
associated with INH resistance.   
 
3.1.1.2.  ahpC  
It has been observed that a loss of katG activity due to the S315T amino acid substitution is 
often accompanied by an increase in expression of an alkyl hydroperoxide reductase (ahpC) 
protein that is capable of detoxifying damaging organic peroxides (Sherman et al., 1996). Five 
different nucleotide alterations have been identified in the promoter region of the ahpC gene, 
which lead to over expression of ahpC and INH resistance (Ramaswamy and Musser, 1998). 
AhpC overexpression exerts a detoxifying effect on organic peroxides within the cell and 
protects the bacteria against oxidative damage but does not provide protection against INH. 
KatG expression can also be up regulated under conditions of oxidative stress. The correlation 
between polymorphic sites in the ahpC regulatory region with INH resistance in M. tuberculosis 
requires further examination.   
 
3.1.1.3.  inhA  
One of the targets for activated INH is the protein encoded by the inhA locus. InhA is an enoyl–
acyl carrier protein (ACP) reductase which is proposed to be the primary target for resistance to 
INH and ethionamide (ETH) (Banerjee et al., 1994). ETH, a second line drug, is a structural 
analog of INH that is also thought to inhibit mycolic acid biosynthesis and several studies have 
suggested that low-level INH resistance is correlated with resistance to ETH. Activated INH 
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binds to the InhA-NADH complex to form a ternary complex that results in inhibition of 
mycolic acid biosynthesis. Six point mutations associated with INH resistance within the 
structural inhA gene have been identified (Ile16Thr, Ile21Thr, Ile21Val, Ile47Thr, Val78Ala and 
Ile95Pro) (Ramaswamy and Musser, 1998; Basso and Blanchard, 1998). A Ser94Ala 
substitution results in a decreased binding affinity of inhA for NADH, resulting in mycolic acid 
synthesis inhibition. Although these mutations in the structural InhA gene are associated with 
INH resistance, it is not frequently reported in clinical isolates. InhA promoter mutations are 
more frequently seen and are present at positions -24(G-T), -16(A-G), or -8(T-G/A) and -15(C-
T). These promoter mutations result in over expression of inhA leading to low level INH 
resistance. To date approximately 70-80 % of INH resistance in clinical isolates of M. 
tuberculosis can be attributed to mutations in the katG and inhA genes (Ramaswamy and 
Musser, 1998). 
 
3.1.1.4. kasA  
There seems to be considerable dispute within the literature as to the role of kasA as a possible 
target for INH resistance (Sherman et al., 1996). This gene encodes a β-ketoacyl-ACP synthase 
involved in the synthesis of mycolic acids. Mutations have been described in this gene that 
confers low levels of INH resistance. Genotypic analysis of the kasA gene reveals 4 different 
amino acid substitutions involving codon 66 (GAT-AAT), codon 269 (GGT-AGT), codon 312 
(GGC-AGC) and codon 413 (TTC-TTA) (Ramaswamy and Musser, 1998; Mdluli et al., 1998). 
However, similar mutations were also found in INH susceptible isolates (Lee et al., 1999; Piatek 
et al., 2000). Nevertheless, the possibility of kasA constituting an additional resistance 
mechanism should not be completely excluded. 
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3.1.1.5 ndh  
In 1998 another mechanism for INH resistance in M. smegmatis was described by Miesel et al. 
(Miesel et al., 1998). The ndh gene encodes NADH dehydrogenase that is bound to the active 
site of inhA to form the ternary complex with activated INH. Structural studies have shown that 
a reactive form of INH attacks the NAD (H) co-factor and generates a covalent INH-NAD 
adduct. Mutations in the ndh gene, encoding NADH dehydrogenase, cause defects in the 
enzymatic activity. Thus, defects in the oxidation of NADH to NAD result in NADH 
accumulation and NAD depletion (Lee et al., 2001). These high levels of NADH can then inhibit 
the binding of the INH-NAD adduct to the active site of the InhA enzyme (Rozwarski et al., 
1998; Miesel et al., 1998). Prominent point mutations in the ndh gene at codons 110 and 268 
(T110A and R268H) were detected in 9.5% of INH resistant samples. These similar mutations 
were not detected in the INH susceptible group (Lee et al., 2001). 
 
3.1.2 Rifampincin  
RIF was fist introduced in 1972 as an anti-TB drug and has excellent sterilizing activity (Rattan 
et al., 1998; Ramaswamy and Musser, 1998). The action of RIF in combination with PZA has 
allowed a shortening of routine TB treatment from 1 year to 6 months. RIF in combination with 
INH forms the backbone of short-course chemotherapy. It is interesting to note that mono 
resistance to INH is common but mono resistance to RIF is quite rare. It has thus been proposed 
that resistance to RIF can be used as a surrogate marker for MDR-TB as nearly 90% of RIF 
resistant strains are also INH resistant (Somoskovi et al., 2001). RIF interferes with transcription 
by the DNA-dependent RNA polymerase. RNA polymerase is composed of four different 
subunits (α, β, β’ and σ) encoded by rpoA, rpoB, rpoC and rpoD genes respectively. RIF binds to 
the β-subunit hindering transcription and thereby killing the organism. Extensive studies on the 
rpoB gene in RIF resistant isolates of M. tuberculosis identified a variety of mutations and short 
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deletions in the gene. A total of 69 single nucleotide changes; 3 insertions, 16 deletion and 38 
multiple nucleotide changes have been reported (Herrera et al., 2003).  More than 95% of all 
missense mutations are located in a 51bp core region (rifampin resistance determining region) of 
the rpoB gene between codons 507-533 with the most common changes in codons Ser531Leu, 
His526Tyr and Asp516Val. These changes occur in more than 70% of RIF resistant isolates 
(Rattan et al., 1998; Ramaswamy and Musser, 1998; Herrera et al., 2003). Furthermore, the 
minimal inhibitory concentration (MIC) showed that high level of RIF resistance is associated 
with mutations in codon 526 and 531, whereas alterations in codon 511,516, 518 and 522 result 
in low level RIF resistance.   
 
3.1.3. Pyrazinamide 
PZA, a nicotinamide analog, was first discovered to have anti-TB activity in 1952.  PZA targets 
an enzyme involved in fatty-acid synthesis and is responsible for killing persistent tubercle 
bacilli in the initial intensive phase of chemotherapy (Somoskovi et al., 2001). However, during 
the first two days of treatment, PZA has no bactericidal activity against rapidly growing bacilli 
(Zhang and Mitchison, 2003). PZA on the other hand has effective sterilizing activity and 
shortens the chemotherapeutic regiment from 12 to 6 months. PZA is a prodrug which is 
converted to its active form, pyrazinoic acid (POA) by the pyrazinamidase (PZase) encoded by 
pncA. The activity of PZA is highly specific for M. tuberculosis, as it has no effect on other 
mycobacteria. Mycobacterium bovis is naturally resistant to PZA due to a unique C-G point 
mutation in codon 169 of the pncA gene. PZA is only active against M. tuberculosis at acidic pH 
where POA accumulates in the cytoplasm due to an ineffective efflux pump. Accumulation of 
POA results in the lowering of intracellular pH to a level that inactivates a vital fatty acid 
synthase (Zimhony et al., 2004). Cloning and characterization of the M. tuberculosis pncA gene 
by Scorpio et al. (Scorpio and Zhang, 1996) showed that pncA mutations conferred PZA 
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resistance. Various pncA mutations have been identified in more than 70 % of PZA resistant 
clinical isolates scattered throughout the pncA gene but thus far no mutational hot spot has been 
identified (Scorpio and Zhang, 1996),(Sreevatsan et al., 1997b; Scorpio et al., 1997). In a study 
from Peru it was found that 59 % of MDR patients also had M. tuberculosis resistant to 
PZA(Saravia et al., 2005). PZA susceptibility testing is not done routinely in many countries due 
to technical difficulties. Thus the extent of PZA resistance globally is largely unknown. A study 
done by Louw et al (Louw et al., 2006) showed that PZA resistance is common amongst drug-
resistant clinical M. tuberculosis isolates from South Africa. PZA resistance was shown to be 
strongly associated with MDR-TB and therefore it was concluded that PZA should not be relied 
upon in managing patients with MDR-TB in this setting. PZA resistant isolates had diverse 
nucleotide changes scattered throughout the pncA gene. Mutations in the pncA gene correlate 
well with phenotypic resistance to PZA. However, PZA resistant isolates without pncA 
mutations were also observed suggesting that another mechanism may be involved in conferring 
PZA resistance in these isolates. In addition, not all mutations (e.g. Thr114Met) were associated 
with PZA resistance. In summary, the complexity of PZA resistance makes the development of 
molecular methods for rapid diagnosis difficult.  
 
3.1.4. Ethambutol 
EMB, a first line drug, is used in combination with other drugs and is specific to the 
mycobacteria. EMB inhibits an arabinosyl transferase (embB) involved in cell wall biosynthesis 
(Takayama and Kilburn, 1989). Telenti et al. (Telenti et al., 1997) identified 3 genes, designated 
embCAB, that encode homologous arabinosyl transferase enzymes involved in EMB resistance. 
Various studies have identified five mutations in codon 306 [(ATG-GTG), (ATG-CTG), (ATG-
ATA), (ATG-ATC) and (ATG-ATT)] which result in three different amino acid substitutions 
(Val, Leu and Ile) in EMB-resistant isolates (Lee et al., 2002; Sreevatsan et al., 1997c; 
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Mokrousov et al., 2002b; Ramaswamy et al., 2000). These five mutations are associated with 70-
90 % of all EMB resistant isolates (Ramaswamy and Musser, 1998). Missense mutations were 
identified in three additional codons: Phe285leu, Phe330Val and Thr630Ile in EMB resistant 
isolates. MIC’s were generally higher for strains with Met306Leu, Met306Val, Phe330Val and 
Thr630Ile substitutions than those organisms with Met306Ile substitutions. Mutations outside of 
codon 306 are present but quite rare. In a study recently done by Johnson et. al. (Johnson et al., 
2006) it was shown that genotypic analysis identified mutations at codon 306 of the embB gene 
rendering resistance to EMB. However, routine phenotypic analysis failed to identify EMB 
resistance in 91.4 % of resistant isolates in this setting and confirm the difficulty of EMB 
phenotypic testing. The inability to accurately detect true EMB resistance by the culture based 
method has a negative impact on the TB control program. Molecular–based methods offer a 
rapid diagnosis of EMB resistance and could thereby benefit the management of TB patents 
within days. However a number of EMB phenotypic resistant isolates (about 30 %) still lack an 
identified mutation in embB. There is therefore a need to fully understand the mechanism of 
EMB resistance in clinical isolates.   
 
3.1.5. Streptomycin 
STR, an aminocyclitol glycoside, is an alternative first line anti-TB drug recommended by the 
WHO (Cooksey et al., 1996). STR is therefore used in the retreatment of TB cases together with 
the four drug regimen that includes INH, RIF, PZA and EMB (Brzostek et al., 2004). The effect 
of STR has been demonstrated to take place at the ribosomal level (Telenti et al., 1993). STR 
interacts with the 16S rRNA and S12 ribosomal protein (rrs and rpsL) (Escalante et al., 1998; 
Finken et al., 1993; Sreevatsan et al., 1996; Abbadi et al., 2001), inducing ribosomal changes, 
which cause misreading of the mRNA and inhibition of protein synthesis. Although STR is a 
recommended anti-TB drug, is it less effective against M. tuberculosis than INH and RIF.  Point 
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mutations in STR resistant isolates have been reported in rrs and rpsL genes in 65-67 % of STR 
resistant isolates (Ramaswamy and Musser, 1998). In the rrs gene a C-T transition at positions 
491, 512 and 516, and a A-C/T transversion at position 513 were observed in the highly 
conserved 530 loop. The 530 loop region is part of the aminoacyl–tRNA binding site and is 
involved in the decoding process (Carter et al., 2000). The C-T transition at codon 491 is not 
responsible for resistance to STR as it occurs in both STR resistant and susceptible isolates but is 
strongly associated with the global spread of M. tuberculosis with a Western Cape F11 genotype 
(van Rie et al., 2001; Victor et al., 2001). Other mutations in the 915 loop [903 (C-A/G) and 904 
(A-G)] have also been reported to have an association with STR resistance (Carter et al., 2000). 
Mutations in the rpsL gene at codon 43 (AAG-AGG/ACG) (Lys-Arg/Thr) and codon 88 (AAG-
AGG/CAG) (Lys-Arg/Gln) are associated with STR resistance. MIC analysis of STR resistant 
isolates indicate that amino acid replacements in the rpsL genes correlate with a high level of 
resistance, whereas mutations in the rrs gene correlate with an intermediate level of resistance 
(Cooksey et al., 1996) (Meier et al., 1996). In addition, it has been suggested that low levels of 
STR resistance are also associated with altered cell permeability or rare mutations which lie 
outside of the rrs and rpsL genes.   
 
3.2. SECOND LINE DRUGS USED IN TB TREATMENT 
According to the WHO the following drugs can be classified as second line drugs: 
aminoglycosides (kanamycin and amikacin) polypeptides (capreomycin, viomycin and 
enviomycin), fluoroquinolones (ofloxacin, ciprofloxacin, and gatifloxacin), D-cycloserine and 
thionamides (ethionamide and prothionamide) (World Health Organization, 2001).  
Unfortunately, second-line drugs are inherently more toxic and less effective than first-line drugs 
(World Health Organization, 2001). Second line drugs are mostly used in the treatment of MDR-
TB and as a result prolong the total treatment time from 6 to 9 months (Cheng et al., 2004). The 
current understanding of molecular mechanisms associated with resistance to second line drugs 
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are summarized in Table 3. The phenotypic methods to detect resistance to second line drugs are 
less well established and the molecular mechanisms of resistance are also less defined. 
 
3.2.1 Fluoroquinolones 
Ciproflaxin (CIP) and ofloxacin (OFL) are the two fluoroquinolones (FQs) used as second-line 
drugs in MDR-TB treatment (World Health Organization, 2001). The quinolones target and 
inactivate DNA gyrase, a type II DNA topoisomerase (Cynamon and Sklaney, 2003; Ginsburg et 
al., 2003; Rattan et al., 1998). DNA gyrase is encoded by gyrA and gyrB (Rattan et al., 1998; 
Takiff et al., 1994) and introduces negative supercoils in closed circular DNA molecules (Rattan 
et al., 1998; Ramaswamy and Musser, 1998).  The quinolone resistance-determining region 
(QRDR) is a conserved region in the gyrA (320 bp) and gyrB (375 bp) genes (Ginsburg et al., 
2003) which is the point of interaction of FQ and gyrase (Ginsburg et al., 2003).  Missense 
mutations in codon 90, 91, and 94 of gyrA are associated with resistance to FQs (Takiff et al., 
1994; Xu et al., 1996).  A 16-fold increase in resistance was observed for isolates with a 
Ala90Val substitution, a 30-fold increase for Asp94Asn or His94Tyr and a 60-fold increase for 
Asp94Gly (Xu et al., 1996).  A polymorphism at gyrA codon 95 is not associated with FQ 
resistance, and is used, with the katG463 polymorphism, to classify M.  tuberculosis into 3 
phylogenetic groups (Sreevatsan et al., 1997a). 
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Table 3. Properties of Resistance to Various Second-line Anti-TB Drugs 
 
Legend to table 3. a) Minimum inhibitory concentration.  b) Polymerase chain reaction- single strand conformation polymorphism.  c) Polymerase chain reaction- 
Restriction fragment length polymorphism.   
 
Second-line drug 
Gene 
locus Gene product 
Known 
polymorphism 
Most frequently 
mutated codons 
associated with 
resistance MIC a (μg/ml) 
Methods for genotypic 
detection of resistance Reference 
Fluoroquinolones 
Ofloxacin 
Cipromycin 
gyrA DNA gyrase gyrA 95  gyr 90, 91, 94 OFL: 1.0-2.0 CIP: 0.5-4.0 
Cloning & expression 
PCR-SSCPb 
DNA sequencing 
(Takiff et al., 1994; Pletz et 
al., 2004; Rattan et al., 1998; 
Ginsburg et al., 2003; Cheng 
et al., 2004) 
Aminoglycosides 
Kanamycin 
Amikacin 
rrs 16 S rRNA  rrs 1400 KAN: > 200 AMI: > 256 
IS6110-RFLP 
PCR-RFLPc 
(Ramaswamy and Musser, 
1998; Takiff et al., 1994; 
Taniguchi et al., 1997; Suzuki 
et al., 1998; Ramaswamy et 
al., 2004; Vannelli et al., 
2002) 
inhA enoyl-ACP reductase inhA21, 94, 44 ≥ 25 
ethA Flavin monooxygenase  ≥200 Ethionamide 
ethR Transcriptional repressor 
 
  
DNA Sequencing 
(Baulard et al., 2000; Morlock 
et al., 2003; Cynamon and 
Sklaney, 2003) 
alr D-alanine racemase 
D- cycloserine 
ddl D-alanine: D-alanine ligase 
  ≥ 300 Cloning & expression DNA Sequencing 
(Caceres et al., 1997; Feng 
and Barletta, 2003) 
Viomycin  rrs 16S rRNA   20 DNA Sequencing 
(Ramaswamy and Musser, 
1998; Taniguchi et al., 1997; 
Suzuki et al., 1995) 
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3.2.2. Aminoglycosides 
Kanamycin (KAN) and Aminokacin (AMI) are aminoglycosides which inhibit protein synthesis 
and thus cannot be used against dormant M. tuberculosis. Aminoglycosides bind to bacterial 
ribosomes and disturb the elongation of the peptide chain in the bacteria. Mutations in the rrs 
gene encoding for 16s rRNA are associated with resistance to KAN and AMI. Nucleotide 
changes at positions 1400, 1401 and 1483 of the rrs gene have been found to be specifically 
associated with KAN resistance (Suzuki et al., 1998). An A→G change at codon 1400 in the rrs 
gene showed resistance to KAN of MICs more that 200 μg/ml (Taniguchi et al., 1997; Suzuki et 
al., 1998).   
 
32.3. Ethionamide 
Ethionamide (ETH) is an important drug in the treatment of MDR-TB, and is mechanistically 
and structurally analogous to INH. Like INH, ETH is also thought to be a prodrug that is 
activated by bacterial metabolism. The activated drug then disrupts cell wall biosynthesis by 
inhibiting mycolic acid synthesis. Mutations in the promoter of the inhA gene are associated with 
resistance to INH and ETH (Morlock et al., 2003).  EthA catalyses a two step activation of ETH 
and gene alterations leading to reduced EthA activity lead to ETH resistance (Engohang-Ndong 
et al., 2004; Morlock et al., 2003; Vannelli et al., 2002). The expression of ethA is under the 
control of the neighbouring ethR gene encoding a repressor. EthR negatively regulates the 
expression of ethA, by binding upstream of ethA to suppress ethA expression (Engohang-Ndong 
et al., 2004).   
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3.10 D-Cycloserine 
D-cycloserine (DCS) is a cyclic analog of D-alanine which is one of the central molecules of the 
cross linking step of peptidoglycan assembly (Ramaswamy and Musser, 1998; Feng and 
Barletta, 2003; David, 2001; Caceres et al., 1997). DCS inhibits cell wall synthesis by competing 
with D-Alanine for the enzymes D-alanyl-D-alanine synthetase (Ddl) and D-alanine racemase 
(Alr) and also inhibiting the synthesis of these proteins. Over expression of alr cause DCS 
resistance. A G→T transversion in the alr promoter may lead to the overexpression of alr (Feng 
and Barletta, 2003; Ramaswamy and Musser, 1998). 
 
3.11 Peptides 
Viomycin (VIO) and capreomycin (CAP) are basic peptide antibiotics that inhibit prokaryotic 
protein synthesis and are used as second-line anti-TB drugs. Earlier studies have shown that 
resistance to VIO in M.  smegmatis is caused by alterations in the 30S or 50S ribosomal subunits 
(Taniguchi et al., 1997).  Mutations in the rrs gene that encodes the 16S rRNA is associated with 
resistance to VIO and CAP, specifically a G→A or G→T nucleotide change at codon 1473 
(Taniguchi et al., 1997). 
 
4.  MOLECULAR METHODS TO PREDICT DRUG RESISTANCE 
M. tuberculosis is a very slow growing organism and the use of molecular methods for the 
identification of mutations in resistance-causing genes may offer a means to rapidly screen M. 
tuberculosis isolates for antibiotic resistance. Mutation screening methods are fast and include 
methods such as DNA sequencing, probe based hybridization methods, PCR-RFLP, single–
strand conformation polymorphism (SSCP), heteroduplex analysis (HA), molecular beacons and 
ARMS-PCR (Victor et al., 2002).  The end results for each of these methods are given as a 
combined photo in Figure 2.   
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4.1. Sequencing 
PCR amplification followed by DNA sequencing is the most widely used technique to identify 
mutations associated with drug resistance in TB (Victor et al., 2002). This technique is costly 
and require expertise, which make it unpractical for use in routine laboratories, especially in 
developing countries, where simple, cost effective drug susceptibility testing is needed (Victor et 
al., 2002). 
 
4.2. Probe-Based Hybridization Methods 
In these assays, amplified PCR products of genes known to confer drug resistance are hybridized 
to an allele-specific labeled probe that is complementary to the wild type or mutant sequence of 
the gene. This can then be visualized by autoradiography, enhanced chemiluminescence, alkaline 
phosphatase or other detection systems. These methods include the Dot-blot and Line blot essays 
and the commercially available INNO-LIPA RIF-TB test (Innogenetics, Belgium) (Victor et al., 
1999; Mokrousov et al., 2004). 
 
4.3.  PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) 
Mutations associated with resistance can be identified by digestion of amplified PCR products 
with a restriction enzyme that cuts at the specific polymorphic DNA sequence followed by gel 
electrophoresis. Since not all mutations result in the gain or loss of a restriction site, general use 
of RFLP to screen for mutations associated with drug resistance  
is limited (Victor et al., 2002). 
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Figure 2: Molecular Methods for Detecting Gene Mutations Associated with Resistance to Anti-TB Drugs 
Legend to figure 2.  A-E are typical examples of final results obtained by PCR-based mutation screening methods.  The DNA template can be pure DNA extracted from a culture, sputum or crude DNA templates prepared 
from culture or sputum.  In all the examples PCR amplification of the DNA is followed by the different mutation detection methods (A-E). 
A: ARMS-PCR analysis of embB gene.  Lane 1 and 8 = Molecular marker and Samples 5 and 6 are mutants.  B: Molecular beacon genotyping of the rpoB gene showing a T→C mutation.  C: Sequence analysis showed a 
C→T mutation at nt161 in the pncA gene D: SSCP analysis with samples having different mutations (visualized as different band mobility shifts) in the of rpoB gene.  Heteroduplex analysis would give similar band 
mobility shifts on the gel.  E: DOT-BLOT analysis with rpsL 43 mutant probe showing wild type (lane D8) and mutant (lane C8) controls and mutant (STR resistant) clinical isolates in B1, B3, C4, D5, C6 and C8.   
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4.4. Single Stranded Conformation Polymorphism Analysis (SSCP) 
SSCP is a gel based method that can detect short stretches of DNA approximately 175-250bp in 
size. Small changes in a nucleotide sequence result in differences in secondary structures as well 
as measurable DNA mobility shifts that are detected on a non-denaturing polyacrylamide gel. To 
date various studies have applied PCR-SSCP to identify mutational changes associated with 
drug resistance in M. tuberculosis for frontline drugs like, RIF and INH (Kim et al., 2004; 
Cardoso et al., 2004; Fang et al., 1999; Heym et al., 1995; Pretorius et al., 1995). However, 
PCR-SSCP analysis has been found to be technically demanding and not sufficiently sensitive. 
Furthermore SSCP conditions must be carefully evaluated since not all mutations will be 
detected under the same conditions. 
 
4.5 Heteroduplex Analysis (HA) 
HA depends on the conformation of duplex DNA when analyzed in native gels.  Heteroduplexes 
are formed when PCR amplification products from known wild type and unknown mutant 
sequences are heated and re-annealed.  The DNA strand will form a mismatched heteroduplex if 
there is a sequence difference between the strands of the wild type and tested DNA. These 
heteroduplexes have an altered electrophoretic mobility when compared to homoduplexes, since 
the mismatches tend to retard the migration of DNA during electrophoresis. There are two types 
of heterodoplexes. The "bubble" type is formed between DNA fragments with single base 
differences and the bulge type is formed when there are deletions or insertions present within the 
two fragments.  Recently, temperature mediated HA has been applied to the detection of 
mutations associated with mutations in rpoB, katG, rpsL, embB and pncA genes (Mohamed et 
al., 2004; Cooksey et al., 2002). Neither HA nor the SSCP analysis are 100% sensitive although 
Rosetti et al. found that HA detected more mutants (Nataraj et al., 1999).  However, HA has 
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certain disadvantages in that it has been found to be insensitive to G-C rich regions and is very 
time consuming (Nataraj et al., 1999). 
 
4.6. Molecular Beacons 
Molecular beacons are single-stranded oligonucleotide hybridization probes which can be used 
as amplicon detector probes in diagnostic assays. A beacon consists of a stem-loop structure in 
which the stem contains a fluorophore on one arm and a quencher on the other end of the arm. 
The loop contains the probe which is complementary to the target DNA. If the molecular beacon 
is free in a solution it will not fluoresce, because the stem places the fluorophore so close to the 
non-fluorescent quencher that they transiently share electrons, eliminating the ability of the 
fluorophore to fluoresce. However, in the presence of complementary target DNA the probe 
undergoes a conformational change that enables them to fluoresce brightly. Different colored 
fluorophores (different primers) can be used simultaneously to detect multiple targets (each 
target will give a different color) in the same reaction. Molecular beacons are very specific and 
can discriminate between single nucleotide substitutions. Thus they are ideally suited for 
genotyping and have been used in the detection of drug resistance in M. tuberculosis (El Hajj et 
al., 2001; Piatek et al., 2000; Piatek et al., 1998). 
 
4.7. Amplification Refractory Mutation System (ARMS)-PCR 
ARMS also known as allelic specific PCR (ASPCR) or PCR amplification of specific alleles 
(PASA) is a well established technique used for the detection of any point mutation or small 
deletions (Newton et al., 1989). ARMS-PCR, is usually a multiplex reaction where three (or 
more) primers are used to amplify the same region simultaneously. One of the three primers is 
specific for the mutant allele and will work with a common primer during amplification. The 
mismatch is usually located at or near the 3' end of the primer. The third primer will work with 
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the same common primer to generate an amplified fragment which is larger than the fragment 
from the mutant allele primer - this serves as an internal control for amplification. Amplification 
is detected by gel electrophoresis and the genotypic classification is determined by assessing 
which amplification products are present. An amplification product should always be present in 
the larger internal control amplified fragment; if this is the case then the absence or presence of 
the smaller product will indicate the presence or absence of a mutant allele. This technique has 
successfully been used for the detection of mutations associated with RIF resistance in M. 
tuberculosis (Fan et al., 2003). Figure 2A indicates how the amplified products in the multiplex 
reaction are distinguished on a gel. 
 
5.  APPLICATIONS  
One of the major advantages of PCR based methods is the speed by which the result can be 
obtained (Siddiqi et al., 1985; Snider, Jr. et al., 1981; Tarrand and Groschel, 1985). It is 
envisaged that molecular techniques may be important adjuncts to traditional culture based 
procedures to rapidly screen for drug resistance. Prospective analysis and intervention to prevent 
transmission may be particularly helpful in areas with ongoing transmission of drug resistant 
strains as reported previously (van Rie et al., 1999). In addition, molecular prediction may also 
be useful in drug surveillance studies to further improve the confidence limit of the data in these 
studies if this test is performed on a subset of the samples. Enhanced efforts are necessary to 
better understand the molecular mechanisms of resistance to second line anti-TB drugs in 
clinical isolates. However, implementation for both rapid diagnosis and surveillance requires 
proper quality control guidelines and controls, which is currently not in place yet for molecular 
prediction of drug resistance in TB. Although molecular methods are more rapid, and can be 
done directly from a clinical sample there are important limitations when compared to 
conventional phenotypic methods. These include a lack of sensitivity since not all molecular 
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mechanisms leading to drug resistance are known, therefore not all resistant isolates will be 
detected. Molecular methods may also predict resistance genotypes that are expressed at levels 
that may not clinically be relevant (Victor et al., 2002).   
 
Transmission and Epidemic Drug Resistant Strains  
There is much debate about the relative contribution of acquired and primary resistance to the 
burden of drug resistant TB in different communities. This controversy focuses on whether 
MDR strains are transmissible or whether the mutations that confer drug resistance also impair 
the reproductive function of the organism (fitness of the strain). Evidence that MDR strains have 
the potential to transmission comes from a series of MDR-TB outbreaks that have been reported 
over the past decade. These have been identified in hospitals (Fischl et al., 1992; Edlin et al., 
1992; Bifani et al., 1996; Cooksey et al., 1996), amongst health care workers (Beck-Sague et al., 
1992; Pearson et al., 1992; Jereb et al., 1995) and in prisons (Valway et al., 1994) and have 
focused attention on MDR-TB as a major public health issue. Application of molecular 
epidemiological methods was central to the identification and description of all these outbreaks.   
 
The most extensive MDR-TB outbreak reported to date occurred in 267 patients from New 
York, who were infected by Beijing/W genotype (Frieden et al., 1996). This cluster of cases 
included drug resistant isolates that were resistant to all first-line anti-TB drugs. The authors 
speculate that the delay in diagnosis and administering appropriate therapy resulted in 
prolonging infectiousness and placed healthcare workers and other hospital residents (or 
contacts) at risk of infection for nosocomial infection. This difficult-to-treat strain has 
subsequently disseminated to other US cities and Paris and the authors showed by using 
molecular methods, how this initially fully drug susceptible strain clonally expanded to result in 
a MDR phenotype by sequential acquisition of resistance conferring mutations in several genes 
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(Bifani et al., 1996). Since then, the drug resistant Beijing/W genotype has been the focus of 
extensive investigations and Beijing drug resistant and susceptible genotypes have been found to 
be widely spread throughout the world (Glynn et al., 2002), including in South Africa (van Rie 
et al., 1999) and Russia (Mokrousov et al., 2002a). Beijing/W genotypes can be identified by 
their characteristic multi-banded IS6110 restriction fragment-length polymorphism (RFLP) 
patterns, a specific spoligotype pattern characterized by the presence of spoligotype spacers 35-
43 (Bifani et al., 2002) and resistance conferring gene mutations. Although these data led many 
to propose that Beijing/W strains behaved differently from other strains, more recent work 
suggests that MDR outbreaks are not limited to the Beijing/W genotype. Smaller outbreaks 
involving other MDR-TB genotypes have been reported in other settings such as the Czech 
Republic, Portugal and Norway (Kubin et al., 1999; Portugal et al., 1999). However, since much 
of the MDR burden falls in developing countries in which routine surveillance does not usually 
include molecular fingerprinting, little is known about the characteristics of circulating drug 
resistant strains in much of the world. It is therefore possible that there are other MDR strains, as 
widespread as Beijing/W, which have not been recognized and reported as such.   
 
 
FUTURE  
Enhanced efforts are necessary to better understand the molecular mechanisms of resistance in 
second line anti-TB drugs in clinical isolates. The next generation of molecular methods for the 
prediction of drug resistance in M. tuberculosis will possibly consists of matrix hybridization 
formats such as DNA oligonucleotide arrays on slides or silicon micron chips (Castellino, 1997; 
Vernet et al., 2004), particularly if these systems can be fully automated and re-used. This may 
be particularly useful for mutations in the rpoB gene, which can serve as a marker for MDR-TB 
(Watterson et al., 1998) and also for the multiple loci that are involved in INH resistance (Table 
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1). Selection of a limited number of target mutations which enable the detection of the majority 
of drug resistance (van Rie et al., 2001) would be useful in this strategy. It is essential that 
developments for new techniques must consider the fact that the majority of drug resistant cases 
occur in resource-poor countries (Raviglione et al., 1995) and therefore the methodologies must 
not only be cheap but also robust.   
 
There are other rapid methods which do not depend on the detection of mutations to predict drug 
resistance. One promising method is phage amplification technology in which 
mycobacteriophages (bacteriophages specific for mycobacteria) are used as an indicator of the 
presence of viable M. tuberculosis in a clinical specimen (Albert et al., 2002; Eltringham et al., 
1999; McNerney et al., 2000). The phage assay can also be adapted for the detection of drug 
resistance. 
 
Application of rapid methods to break chains of ongoing transmission of drug resistant TB will 
increasingly become important as recent mathematical modeling indicate that the burden of 
MDR-TB cannot be contained in the absence of specific efforts to limit transmission (Cohen and 
Murray, 2004; Blower and Chou, 2004). This may include rapid detection of drug resistance by 
molecular methods.   
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ABSTRACT 
Sputum samples were collected from tuberculosis (TB) patients in a high TB incidence area in 
the Western Cape, South Africa. The aim of this study was to evaluate the performance and time 
to diagnosis of a genotypic drug susceptibility testing (DST) method. During June 2000 and 
November 2003, a total of 1540 samples were sent for DST to the national health laboratory 
services, and of those, a phenotypic DST result was obtained for 1373 samples whereas a 
genotypic DST result was obtained for 1301 of 1540 samples. Performance-based calculations 
were done on 1244 samples for which both a phenotypic and genotypic result were available. 
The reproducibility of the genotypic and phenotypic DST methods was 97 % and 95 %, 
respectively. The sensitivity and specificity of the genotypic DST method was 68 % and 99 % 
for Isoniazid and 87 % and 99 % for Rifampicin, respectively. Smear gradation was found to 
influence the performance of the genotypic DST method. The genotypic DST method gave 
accurate DST results for 75 % of the samples within 20 days (range, 15-25), whereas the 
phenotypic DST results were only available for 75 % of the samples after 38 days (range, 26-
115) (p<0.001). This study showed that the genotypic DST could improve TB control by rapid 
diagnosis of drug resistant tuberculosis, thereby decreasing the risk of transmission.   
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INTRODUCTION 
In resource poor countries, the World Health Organization (WHO) guidelines recommend the 
diagnosis of tuberculosis (TB) by smear microscopy in all new TB cases and smear microscopy, 
culture and drug susceptibility testing (DST) in re-treatment cases (18). If a new case fails to 
convert after 2 to 3 months of first line therapy, culture and DST is requested. Routine 
phenotypic DST methods are culture based and is initially done to detect isoniazid (INH) and 
rifampicin (RIF) resistance. If resistance to INH and RIF is found, DST for ethambutol (EMB) is 
requested. DST usually takes between 3-6 weeks, resulting in long diagnostic delays. These 
delays are further exacerbated in new cases with primary drug resistance, given that DST is only 
initiated after 2 to 3 months of first line therapy. Such long delays and the administration of 
inappropriate therapy during the delay period may lead to the further acquisition of drug 
resistance, as well as the dissemination of drug resistant strains through transmission. Thus, to 
improve the outcome and prevent transmission of drug resistant TB, robust and effective 
alternative diagnostic tests are required that will enable the identification of drug resistant TB 
(DR-TB) within a few days after sputum collection.  
 
Resistance to first line anti-TB drugs develops through the sequential accumulation of mutations 
in genes targeted by the different drugs. To date, 11 genes have been linked to resistance to the 
first line anti-TB drugs (7,15); katG, inhA ,inhA promoter, ahpC, kasA and ndh for INH 
resistance; rpoB for RIF resistance embB for EMB resistance, pncA for pyrazinimide (PZA) 
resistance and rpsL and rrs for streptomycin (STR) resistance (8,16). Mutations in specific 
codons can therefore be used to rapidly detect drug resistance, since drug susceptible samples 
lack the corresponding gene mutation.  In the last few years this concept has led to considerable 
progress in the development of screening tools for the detection of DR-TB.  The first paper on 
mutation detection for drug resistant TB was published in 1993 (11) and since then, numerous 
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markers and molecular methods have been described to detect drug resistant gene mutations. 
These methods include polymerase chain reaction (PCR) or other nucleic acid amplification 
methods followed by DNA sequencing, probe methods, PCR-restriction fragment length 
polymorphism (PCR-RFLP), single–strand conformation polymorphism (SSCP), heteroduplex 
analysis (HA), molecular beacons and ARMS-PCR (3,4,7,9,11,14,17). Application of these 
molecular tools proved to be rapid and effective in low burden settings. 
 
The aim of this study was to compare the performance (sensitivity, specificity and 
reproducibility) and time to diagnosis of a molecular genotyping DST method to the “gold 
standard” in order to detect INH and RIF resistance in high incidence TB communities. 
 
 
MATERIALS AND METHODS. 
Study Setting. 
TB cases from the Boland, Overberg, South Cape and Karoo region were treated according to 
the National Tuberculosis programme (NTP) of South Africa. Sputum samples were collected 
from suspect TB cases attending 9 primary health care clinics and a TB referral hospital during 
the period June 2000 and November 2003 and sent to the National Health Laboratory services 
(NHLS) for TB diagnosis by smear microscopy. Sputum from re-treatment and new cases who 
failed to convert after 2 months of intensive phase anti-TB treatment was subjected to culture 
and DST. 
 
Phenotypic DST. 
Sputum samples were decontaminated with a mixture of sodium hydroxide, sodium citrate and 
N-acetyl-L-cysteine and neutralized with sodium phosphate (1). At this point each sample was 
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divided into two equal parts. Part 1 was sent to Division of Molecular Biology and Human 
Genetics, University of Stellenbosch for genotypic DST. Part 2 was used at NHLS for routine 
microscopy, culture and phenotypic DST analysis. Cultures were grown in BACTEC 12B 
medium (Becton Dickinson, Maryland, USA) with PANTA and growth of Mycobacteria was 
confirmed by Ziehl-Neelsen (ZN) staining. All ZN positive samples were then subjected to a 
niacin test to confirm the presence of Mycobacterium tuberculosis complex. If the culture was 
ZN negative after the 35 days of incubation, a final result of negative was reported. DST testing 
was only done on niacin positive cultures using the proportion method on Löwenstein-Jensen 
medium containing critical concentrations of 0.2 µg for isoniazid (INH) or 30 µg for rifampicin 
(RIF). Resistance was defined as 1 % or more bacterial growth in comparison with a control in 
which the tested drug was absent.  
 
Genotypic DST. 
Decontaminated sputum samples (part 1) were collected (usually 20-25 samples) weekly from 
the NHLS for genotypic DST. Each sample was inoculated into 1 ml of BACTEC 12B media, 
which contained 0.1 ml PANTA–plus (Becton Dickinson, Maryland, USA), and incubated in a 
50 ml Falcon tube (Greiner Bio-One, Germany) at 37 °C for 5 days. A negative control 
containing water was inoculated after every 5th sputum sample in a batch to control for possible 
cross-contamination. After short term culture, the bacteria were pelleted by centrifugation at 10 
000 x g for 20 minutes and the supernatant was aspirated into 150 µl. A crude DNA template 
was prepared by boiling each sample at 100 °C for 20 minutes. These crude DNA templates 
were used to PCR amplify chromosomal domains containing mutations associated with INH 
(katg315, inhA-15 promoter) and RIF (rpoB531, rpoB526, rpoB516) resistance as described 
previously (13,14). PCR amplification of each batch was performed in 4 separate rooms to 
minimize amplicon contamination. A water control, DNA from genotypically characterized drug 
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resistant and susceptible controls, and the negative control prepared during short term culture 
were incorporated with each PCR amplification reaction (13). Amplicons generated were 
visualized after electrophoretic fractionation in 1.5 % agarose gel in 1 x TBE buffer and staining 
with ethidium bromide. Ten microliters of the PCR amplified product was then denatured by the 
addition of 190 µL of denaturing buffer containing 0.4 N NaOH and 25 mM EDTA and then 
spotted onto a Hybond-N+ membrane using a dot-blot apparatus (Bio-Rad). Hybridization was 
done using 32P labelled oligonucleotide probes which were directed towards mutations in drug 
resistant genes most frequently found in the local isolates and in other parts of the world as 
described previously (13,14). Results were scored based on discrimination between 
genotypically well-characterized controls on the blot. DNA sequencing was done on selected 
PCR amplified products using the ABI PRISM DNA model 3130xl sequencer (Applied 
Biosystems, Foster City,CA 94404, USA). 
 
Data Analysis 
The statistical program Statistica 7.1 (stasoft, Inc (2005) (www.statsoft.com)) was used to 
calculate the performance (sensitivity and specificity) of the molecular method at a confidence 
interval of 95 %. Reproducibility of the phenotyping and the probe method was calculated by 
comparing follow-up DST results from the same patient, while the accuracy of the genotypic 
DST method was compared to the results obtained by DNA sequencing. The time for reporting 
DST results was calculated by subtracting the date the phenotypic or genotypic DST result was 
available from the date the sputum samples were received. The time for reporting DST for 
samples that had lost viability during phenotypic DST were calculated from the first time that 
specific isolates was received for DST and reported lost viability until a second or third sample 
was requested and the DST results was available. The time for reporting genotypic DST results 
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was calculated from the day a specific batch of samples was received at the University of 
Stellenbosch until the genotypic results were available.  
 
 
RESULTS  
Between June 2000 and November 2003, 3038 sputum samples were collected from patients’ 
resident in the study setting and subjected to culture (Fig 1). DST was requested and performed 
on 1540 of these cultures, of which 1373 (89 %) cultures gave a DST result. The remaining 167 
cultures were either contaminated lost viability or were found to be Non-Tuberculosis 
Mycobacteria (NTM). Phenotypic INH and RIF resistance was identified in 279 (20 %) and 177 
(13 %) of the cultures, respectively. Resistance to both INH and RIF (MDR-TB) was identified 
in 165 (12 %) of the cultures. The reproducibility of the routine phenotypic DST method was 95 
% (kappa value 0.8) when the DST results of sequential follow-up samples were compared. 
 
Genotyping was done on all of the samples submitted for culture and DST testing in order to 
determine the efficiency of mutation detection by the genotyping method. A definitive genotypic 
DST result was obtained for 1301 of the samples. The remaining 239 failed to produce a product 
after PCR amplification. Genotypic DST showed that 188 (14 %) of the samples were INH 
resistant, 155 (12 %) were RIF resistant and 117 (9 %) of the samples were MDR-TB. The 
reproducibility of the genotyping DST method was 97 % (kappa value 0.9) when sequential 
follow-up samples were compared.  Genotypic DST had an accuracy of 97 % (kappa value 0.9) 
when compared to DNA sequencing. Phenotypic DST results were available for 1244 (95.6 %) 
of the PCR positive samples (Table 1). 
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Fig 1. Flow diagram showing phenotypic and genotypic DST of sputum samples. 
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Table 1: Comparative analysis of phenotypic and genotypic DST. 
  n=1244 
 Phenotype Genotype 
INHS 1000 (80 %) 1065 (86 %) 
INHR 244 (20 %) 28 inhA prom (2 %) 
  151 katG (12 %) 
   
RIFS 1095 (88 %) 1102 (89 %) 
RIFR 149 (12 %) 142 (11 %) 
   
MDR 141 (11 %) 108 (9 %) 
                                        Legend to Table 1:  S-susceptible; R-resistant 
 
 
Performance was calculated on 1244 samples for which both a phenotypic and genotypic DST 
results was available. Performance calculations comparing the genotyping DST method to the 
gold standard phenotypic DST method showed a sensitivity and specificity for INH resistance of 
68 % and 99 %, respectively. The positive and negative predictive values were 92 % and 93 %, 
respectively. The sensitivity and specificity for genotypic RIF resistant testing was 87 % and 99 
% respectively, while the positive and negative predictive values were 92 % and 98 % 
respectively. The sensitivity and specificity for genotypic MDR testing were 72 % and 99 %, 
respectively, while the positive and negative predictive values were 94 % and 97 % respectively.   
 
To determine whether smear gradation strongly influenced the predictive value of the 
genotyping method, PCR amplification ability was compared to the sample bacterial load. A 
positive correlation between the bacterial load and amplification was observed, as 6 % (37/311) 
of the high (smear 2+ and 3+) and 12 % (51/881) of the low (smear 1+) bacterial load samples 
were not amplifiable. Smear results were not available for 181 sputum samples.   
To determine whether the genotypic DST method could shorten the interval for diagnosing drug 
resistance, the time to a positive DST result, between the phenotypic and genotypic methods, 
was compared. Genotype DST results were available for 75 % of the samples within 20 days 
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(range, 15-25), whereas 75 % of the phenotype result were only available after 38 days (range, 
26-115) (Fig 2). This difference was statistically significant according to the Wilcoxon matched 
pair test (p<0.001). 
 
Thirty-four (20 %) of the samples that failed to give a phenotypic DST result were PCR 
amplifiable. These samples either lost viability or were contaminated and subsequent samples 
were requested for DST. In these cases the mean delay was 133 days (range 50-1403 days) 
before a phenotypic DST result was available.  In contrast the genotypic DST results were 
available within 27 days (range, 18-30). 
 
 Median 
 25%-75% 
 Non-Outlier Range 
 Outliers
 Extremes
phenotype genotype
0
20
40
60
80
100
120
 
Fig 2. Time to a positive DST result using either phenotypic or genotypic DST. The mean 
diagnostic delay for the phenotypic method was 38days (range 26 to 115), while the mean 
diagnostic delay for the genotypic method was 20 days (range 15 to 25). 
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DISCUSSION 
It is well known that DST for some drugs is difficult due to technical reasons and these results 
are not always accurate (5,6). In addition, it may take up to 6 weeks to get a phenotypic DST 
result and during this time many transmission events may take place.  Alternative methods need 
to be evaluated to improve the speed of diagnosis of DR-TB and especially MDR-TB. Molecular 
techniques have been applied widely to detect mutations associated with specific drugs to 
overcome these problems.  
 
This is a comprehensive study to evaluate the performance (sensitivity and specificity) of a 
genotypic method to detect drug resistance in a high TB incidence area. In this study, we have 
concentrated on identifying the most frequent mutations associated with resistance to INH and 
RIF (9,11). We found that our genotypic DST method compared favourably against the culture 
method for INH and RIF. However, it was noted that the sensitivity for INH was low since many 
of the resistance carrying gene mutations could not be identified.  This observation is not unique 
since the molecular mechanisms for INH resistance are not fully understood and 25-30 % of 
phenotypic INH resistance associated mutations are still unaccounted for (12). An important 
finding was that 75 % of the genotypic results from all samples tested were available in a 
significantly shorter time interval in comparison to conventional culture based phenotyping 
methods. Such a time saving may have important implications for the control of DR-TB as it 
may reduce the chance for further transmission events of DR-TB. Furthermore, the genotypic 
DST method was able to detect drug resistance in samples which lost viability, circumventing 
the need to request follow-up sputum and thus reducing the overall cost and resources as it will 
not be necessary to tract patients in rural areas.  
The performance of any new molecular method will depend on the efficiency of the sample 
preparation procedure. Amplification of drug resistant genes directly from sputum samples 
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without the need for culture remains a major problem. For many genotypic methods PCR 
analysis directly from sputum samples with very low bacterial load is extremely difficult. This 
may be the most important reason why molecular testing has not yet been introduced for routine 
testing on a large scale. We found that the establishment of short term mini-cultures from 
decontaminated sputum samples and the use of a specific Hot star Taq polymerase (Qiagen) 
gave the most consistent results. The implementation of DNA extraction protocols such as the 
nuclisens magnetic extraction kit (Biomérieux, Netherlands) may significantly improve 
detection of drug resistance from scanty positive sputum samples.  
 
In the local community, the majority of drug resistance is due to transmission of a previously 
drug resistant strain (10). Recently, a bleak picture has emerged for TB control programs with 
the discovery of extensively drug resistant TB (XDR-TB) strains, raising concerns of a future 
epidemic of virtually untreatable TB (2). If any genotypic method could rapidly (despite low 
sensitivity) detect the majority of drug resistant strains in a high incidence community, the use of 
such a technique will be an advantage for the control of DR-TB. Therefore, it is urgent that 
molecular methods are developed and evaluated with the aim of rapid detection of MDR- and 
XDR-TB.  
 
From the lessons learned in this study, the following recommendations can be made i) molecular 
methods can aid in the rapid detection of DR-TB. This is particularly useful for the detection of 
RIF resistance which is a marker for MDR-TB and XDR-TB, ii) implementation of any new test 
must be done in close collaboration with clinicians and the TB control program, iii) a positive 
genotype result, for a known drug resistant gene causing mutation, can be regarded as true 
resistance, iv) if possible, discrepant results between genotype and phenotype testing should be 
subjected to DNA sequence analysis, v) resistance genotyping must initially test for RIF 
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resistance followed by testing for other drugs (including genotypic DST for second line drugs to 
identify XDR-TB). We conclude that this study showed that a molecular method to rapidly 
detect drug resistance can add considerable value to the control of DR-TB in a high incidence 
area  
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Abstract   
Objective: To identify chromosomal mutations that confers resistance to ethambutol (EMB) in 
M. tuberculosis. 
Design: Drug resistant (n=235) and drug susceptible (n=117) M. tuberculosis isolates collected 
from the Western Cape in South Africa were subjected to embB gene analysis and the results 
were compared to phenotypic EMB testing. 
Results: Genotypic analysis identified mutations at codon 306 of the embB gene in 20 % 
(n=47/235) of the resistant isolates in comparison to only 1.7 % (n=4/235) which were 
phenotypically resistant to EMB by the agar diffusion method. No gene mutations were detected 
in susceptible isolates.  Phenotypic re-testing in BACTEC demonstrated that the 47 
genotypically resistant isolates were phenotypically resistant to EMB. This implies that 91.4 % 
(n=43/47) of EMB resistance had been phenotypically missed by routine laboratory procedures. 
EMB resistance was closely linked to MDR as 87.2 % (n=41/47) of the EMB resistant isolates 
was resistant to both Isoniazid (INH) and Rifampicin (RIF). A newly developed one-step 
Amplification Refractory Mutation System Polymerase Chain Reaction (ARMS-PCR) method 
correctly detected the EMB resistant genotype. 
Conclusion:  Implementation of more accurate diagnosis of EMB resistance may enhance 
patient management in South Africa since the standardized treatment of MDR-TB with second 
line drugs is currently dependent on the outcome of the EMB resistance test. 
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INTRODUCTION 
Ethambutol (EMB), a first-line anti-tuberculosis (TB) drug, was introduced in 1961 and 
recommended for use in combination with isoniazid (INH), rifampin (RIF), streptomycin (STR), 
and pyrazinamide (PZA) 1. Association studies implicate arabinosyltransferases as the targets for 
EMB, which are involved in the biosynthesis of the cell wall components arabinogalactan (AG) 
and lipoarabinomannan (LAM).  EMB action on the tubercle bacilli is bacteriostatic due to the 
inhibitory effect of the drug in the transfer of AG into the cell wall. This process leads to the 
accumulation of mycolic acid 2. As a result, the synthesis of sugars necessary for cell wall 
construction, is prevented, and thereby cell death follows.   
 
In 1997 Telenti and colleagues 3 used EMB resistant isolates to identify the embCAB gene locus 
involved in the biosynthesis of the mycobacterial cell wall. The M. tuberculosis embCAB locus 
is a 10kb operon that encodes for arabinosyltransferases in three contiguous genes, namely, 
embC, embA and embB, that have a 60 % similarity to each other 3. Sreevatson 4 confirmed the 
finding that certain mutations in the embCAB operon of M. tuberculosis were exclusively 
associated with EMB-resistant clinical isolates 3;4. In particular, amino acid replacements at 
position 306 of embB were represented in approximately 90 % of EMB-resistant isolates, but not 
EMB-susceptible isolates 5-7. Five distinct structural mutations in the embB gene have been 
described, with amino acid replacements of the wild-type Met306 with Ileu, Leu or Val, in EMB 
resistant isolates 8. This finding suggested embB as one of the targets of EMB. Mutations outside 
the 306 codon have been found but are less frequent 7. EMB susceptible isolates lack the 
corresponding gene mutations 4;7.   
 
A close association with gene mutations and phenotypic culture-based EMB susceptibility 
testing will only be evident if the phenotypic test is highly sensitive and specific. This is 
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currently not the case in routine diagnostics laboratories in many countries. Phenotypic EMB 
resistance detection in cultures differs widely and lacks uniformity amongst different 
laboratories 6;9;10. In a quality assurance study done during 1997 between 16 supranational 
reference laboratories within the World Health Organization (WHO) network, a vast lack in 
uniformity amongst phenotypic EMB testing was observed 9. The National Health Laboratory 
Services (NHLS) in Cape Town is a high-throughput routine diagnostic laboratory and receives 
on average 550 samples per day for TB testing. Drug susceptibility testing, which includes 
EMB, is carried out on a subset of these samples by means of the agar proportional method 11;12. 
As from March 2003, drug susceptible testing is only done for INH, RIF and EMB. The 
treatment regimen of MDR-TB cases with second line anti-TB drugs is then based on the 
outcome of the EMB test as recommended by the national TB control program 12. 
 
In this study a molecular approach was used to screen for gene mutations considered to be 
associated with EMB resistance. Clinical isolates found to be resistant (any drug) by routine 
culture drug susceptibility testing, as well as fully drug susceptible isolates were used in this 
investigation. The aim of this study was to correlate mutational analysis at codon 306 of the 
embB gene to EMB culture susceptibility testing of M. tuberculosis isolates in a routine 
laboratory surrounding a high incidence area.  
 
 
STUDY POPULATION AND METHODS  
Isolates Two sets of M. tuberculosis isolates were collected between November 2000 and June 
2003 from 72 rural clinics in the Boland/Overberg and Southern Cape/Karoo region. in the 
Western Cape, South Africa. The first set of 235 drug resistant (resistant against any drug) M. 
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tuberculosis isolates (in BACTEC 12B media) represent one isolate per patient. The second set 
consisted of 117 fully drug susceptible isolates over the same time period from the same region. 
 
Culture drug susceptibility testing   Isolates (n=352) were initially tested for EMB resistance 
in the routine diagnostic laboratory (NHLS) by the agar diffusion method on Middlebrook 7H11 
slants (supplemented with Tween 80 (Merck, Darmstead, Germany) and 100ml Oleic Albumin 
dextrose Catalase (Biolab diagnostics, Gauteng, South Africa)) at a critical EMB concentration 
of 7.5µg/ml.  Results of sensitivity testing were read at 21 days.   
 
Mutational analysis The embB gene was amplified using crude DNA templates and visualized 
on a 1.5 % agarose gel in 1 x TBE buffer with ethidium bromide using a previously described 
method 13. Five microliter of PCR template was used for PCR dot-blot hybridization as 
described previously 13.  Wild type and mutant-specific oligonucleotides, for the embB 306 
codon (Table 1), were used for the detection of mutations associated with EMB resistance. Dot-
blot analysis was carried out as described previously 13.  
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Table 1 Probes used for dot-blot hybridisation 
Probe Sequence Tm Reference 
Emb306wt C CTG GGC atg GCC CGA GTC G 70°C Victor et al. (1999) 
Emb306ATA C CTG GGC AT“a” GCC CGA GTC G 68°C Current 
Emb306ATC C CTG GGC AT“c” GCC CGA GTC G 70°C Current 
Emb 306ATT C CTG GGC AT“t” GCC CGA GTC G 68°C Current 
Emb 306GTG C CTG GGC “g”TG GCC CGA GTC G 72°C Current 
Emb 306CTG C CTG GGC “c”TG GCC CGA GTC G 72°C Current 
Legend to Table 1: atg, wild type probe; AT“a”, AT“c”, AT“t”,”g”TG and “c”TG, mutant probes. 
 
 
Handling of discrepant results Phenotypic re-testing of EMB was done using the 
BACTEC method at a prescribed critical concentration of 2.5µg/ml in the Department of 
Medical Biochemistry, University of Stellenbosch. Each of the isolates was checked weekly, and 
the susceptibility results were recorded between 5-12 days. Discrepant results between 
phenotyping and genotyping were further evaluated by DNA sequencing on selected samples 
with an ABI PRISM DNA sequencer (model 377, Perkin Elmer, Foster City, US).   
 
Performance of Phenotypic and Genotypic test After investigation of all discrepancies, the 
corrected EMB resistance pattern for each of the isolates was determined. The corrected EMB 
resistant pattern was then used as the “gold standard” to evaluate and compare the performance 
of both the phenotype and genotype EMB resistant testing as was done previously 10;14.   
 
Statistics: The difference between phenotypic and genotypic results was calculated using 
the statistical program GraphPad Prism version 4.03.   
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Amplification refractory mutation system (ARMS)-PCR. An ARMS multiplex PCR method 
has been developed to detect EMB associated gene mutations in a one-step PCR reaction. The 
primer sets was Emb151 5’ CGG CAT GCG CCG GCT GAT TC ’3, Emb151wt 5’ ACG GCT 
ACA TCC TGG GCA TG ‘3 and Emb131 5’ TCC ACA GAC TGG GT CGC TG ‘3 at a Tm of 
66°C. For the Hot Star PCR reaction (Qiagen), 5µl crude DNA lysate was added to a PCR mix 
(100µl) containing a 2.25mM MgCl2, 250µM of deoxynucleotide triphosphates, 20µl Q Buffer, 
2.5 units Taq, 10µL Emb 131 reverse primer, 6µl Emb151 forward primer and 6µl Emb151wt 
wild type primer.  DNA amplification of 40 cycles was done as fellows:  95°C for 15min, 95 °C 
for 1min, 66 °C for 1min, 72 °C for 1min, and a final extension of 72 °C for 7min.  PCR 
products were analyzed by electrophoresis on a 1.5% agarose gel and stained with ethidium 
bromide. 
 
 
RESULTS 
Phenotypic drug resistance pattern by routine surveillance. On routine investigation of the 
235 resistant isolates, only 1.7% (4/235) was found to be resistant to EMB using a critical 
concentration of 7.5µg/ml on Middlebrook 7H11 slants (Table 2). Additional BACTEC culture 
analysis confirmed that these four isolates (R120, R179, R212 and R222) were resistant to EMB. 
They were also resistant to other first and second line anti-TB drugs.  
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Table 2: Phenotypic and genotyping of all isolates with a mutant embB306 allele. 
Isolate Resistant Pattern embB306 Corrected Phenotype 
R 162 INH ATA INH, EMB 
R 163 INH ATA INH, EMB 
R 327 INH ATA INH, EMB 
R 7 INH,RIF GTG* INH,RIF, EMB 
R 12 INH,RIF GTG* INH,RIF, EMB 
R 39 INH,RIF ATA* INH,RIF, EMB 
R 132 INH,RIF ATA* INH,RIF, EMB 
R 178 INH,RIF ATA INH,RIF, EMB 
R 269 INH,RIF GTG* INH,RIF, EMB 
R 373 INH,RIF ATA INH,RIF, EMB 
R 296 INH,RIF,ETH ATA INH,RIF,ETH, EMB 
R 1 INH,RIF,STR GTG INH,RIF,STR, EMB 
R 10 INH,RIF,STR ATC INH,RIF,STR, EMB 
R 14 INH,RIF,STR ATC INH,RIF,STR, EMB 
R 17 INH,RIF,STR GTG INH,RIF,STR, EMB 
R 24 INH,RIF,STR ATC INH,RIF,STR, EMB 
R 41 INH,RIF,STR ATA INH,RIF,STR, EMB 
R 44 INH,RIF,STR ATA INH,RIF,STR, EMB 
R 56 INH,RIF,STR ATC INH,RIF,STR, EMB 
R 58 INH,RIF,STR ATC INH,RIF,STR, EMB 
R 60 INH,RIF,STR ATA INH,RIF,STR, EMB 
R 63 INH,RIF,STR ATC INH,RIF,STR, EMB 
R 65 INH,RIF,STR ATA INH,RIF,STR, EMB 
R 73 INH,RIF,STR ATC INH,RIF,STR, EMB 
R 102 INH,RIF,STR ATA INH,RIF,STR, EMB 
R 145 INH,RIF,STR GTG INH,RIF,STR, EMB 
R 221 INH,RIF,STR ATC INH,RIF,STR, EMB 
R 223 INH,RIF,STR ATA INH,RIF,STR, EMB 
R 235 INH,RIF,STR ATA INH,RIF,STR, EMB 
R 364 INH,RIF,STR GTG INH,RIF,STR, EMB 
R 391 INH,RIF,STR ATC INH,RIF,STR, EMB 
R 432 INH,RIF,STR ATC INH,RIF,STR, EMB 
R 439 INH,RIF,STR ATA INH,RIF,STR, EMB 
R 451 INH,RIF,STR ATA INH,RIF,STR, EMB 
R 543 INH,RIF,STR ATC* INH,RIF,STR, EMB 
R 565 INH,RIF,STR ATA* INH,RIF,STR, EMB 
R 590 INH,RIF,STR GTG* INH,RIF,STR, EMB 
 
 
 
 
 
71
R 619 INH,RIF,STR ATC* INH,RIF,STR, EMB 
R 120 INH,RIF,STR,EMB wt* INH,RIF,STR,EMB 
R 40 INH,RIF,STR,ETH ATC* 
INH,RIF,STR,ETH, 
EMB 
R 118 INH,RIF,STR,ETH GTG 
INH,RIF,STR,ETH, 
EMB 
R 394 INH,RIF,STR,ETH ATC 
INH,RIF,STR,ETH, 
EMB 
R 212 INH,RIF,STR,ETH,EMB ATA INH,RIF,STR,ETH,EMB 
R 222 INH,RIF,STR,ETH,EMB ATC INH,RIF,STR,ETH,EMB 
R 257 INH,STR GTG* INH,STR, EMB 
R 479 INH,STR ATA INH,STR, EMB 
R 179 INH,STR,ETH,EMB GTG INH,STR,ETH,EMB 
Legend to Table 2: INH, Isoniazid; RIF, Rifampicin; STR, Streptomycin; EMB, Ethambutol; ETH, Ethionamide; *, Sequence; W, wild type, R, 
resistant, S,Susceptible; MIC, Minimal inhibitory concentration 
 
 
Genotypic resistant Pattern.  Mutations could only be detected in three of the four 
phenotypically EMB resistant isolates which have the following embB306 gene mutations: 
isolate R179 Met306Val (ATG→GTG), R212 Met306Ile (ATG→ATA) and R222 Met306Ile 
(ATG→ATC). No mutations in the embB gene could be detected in isolate R120, even after 
DNA sequencing of the entire gene. Mutations at codon embB306 were present in 47 of 235 
isolates (20 %) phenotypically classified as susceptible to EMB after initial routine screening 
(Table 2). The difference between phenotypic and genotypic results was statistically significant 
(p<0.0001). The following embB306 gene mutations were associated with these 47 isolates: 
ATG-ATA (n=21), ATG-ATC (n=15) and (ATG-GTG) (n=11) respectively. No mutations were 
observed by dot-blot or sequence analysis at codon 306 in the 117 fully EMB susceptible 
isolates from the same geographical area collected during the same time period.   
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Investigation of discrepant results. Forty four isolates showed potential false –negative EMB 
testing by routine screening. Retesting of the culture-based false negative samples by additional 
DNA sequence analysis (n=12) confirmed the initial dot blot results (Table 2). Phenotypic re-
testing by the radiometric BACTEC method confirmed that these isolates were resistant to EMB 
at the critical concentration of 2.5 µg/ml. The results from both phenotypic and genotypic re-
testing were then used to establish the corrected EMB resistant phenotype for each isolate. 
Collectively these results strongly suggest that the additional 43 isolates with embB306 gene 
mutations are indeed resistant to EMB and that 91.4 % of EMB resistance was not detected 
during the initial screening for EMB resistance in the routine laboratory. 
 
Performance of genotypic EMB resistant testing. Comparative analysis showed that both 
phenotype (BACTEC) and genotype method have a high specificity (100 %) and sensitivity (97 
%). However, the specificity and sensitivity of the proportional method was 100 % and 8.3 % 
respectively. Thus the original EMB resistant screening by the phenotypic method was 
extremely low (8.3 %) in comparison to the sensitivity (97 %) of the genotypic and BACTEC 
phenotype methods.  
 
EMB resistance is strongly associated with MDR-TB. Further analyses of the drug 
resistance of the isolates indicated that none of the isolates are EMB mono-resistant.  An 
interesting observation is that EMB resistance was predominantly (87 %) associated with MDR 
isolates; 11 % of isolates were associated with other multiple drug resistant combinations.   
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ARMS-PCR.  An ARMS PCR-based method was develop to improve rapid detection of EMB 
resistance. After PCR amplification a 260 bp DNA fragment for EMB resistant isolates and a 
double band of 260 bp and 150 bp respectively for EMB susceptible isolates was generated 
(Fig.1). Isolates (n=50) screened in a blind study using the ARMS–PCR method corresponded 
100 % to dot-blot analysis done on the same subset of isolates. 
 
 
 
 
 
 
DISCUSSION 
The control of drug resistant TB relies upon the incorporation of drug susceptibility testing as 
part of national TB control programs. Since 1996, drug-susceptibility testing in South Africa has 
only been done on cultures obtained from retreatment cases and new patients with treatment 
failure. This routine drug-susceptibility testing is done by the NHLS, Cape Town, using the agar 
proportion method on Middlebrook slants containing critical concentrations of 0.2 µg/ml INH or 
30 µg/ml RIF. Additional drug-susceptibility testing was done for cultures found to be resistant 
       1            2           3            4             5           6             7         8 
Fig. 1.  ARMS PCR amplification of EMB.  Lane: 2-4 EMB 
resistant isolates lane, 5-6 EMB susceptible isolates, lane: 1 
and 8: DNA size marker IX (Roche) and lane 7: blank
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to INH and/or RIF. In 2002, standardized treatment of MDR-TB was introduced as part of the 
national TB control program and as from March 2003 drug susceptibility testing became limited 
to INH, RIF, and EMB 12. Ethambutol is used during the continuation phase of the standard 
retreatment regiment in South Africa as it is a valuable bacteriostatic agent for preventing the 
emergence of resistance to other TB drugs 12. All retreatment and treatment failure cases are 
initially treated with a combination of INH, RIF, EMB, STR and PZA until the drug 
susceptibility test for INH, RIF and EMB are available. Such testing takes on average two 
months (range 30-98 days). If EMB resistance is identified, EMB is replaced with Cycloserine in 
the second line treatment regimen. Therefore the outcome of EMB drug susceptibility testing is 
critical in deciding the most appropriate treatment regimen. It is well known that testing of 
susceptibility to INH and RIF is more reliable than testing susceptibility to EMB, STR and 
PZA15-17. This study supports previous reports which have raised concern over false negative 
EMB susceptibility results 6;10. In this study, the routine laboratory method for EMB resistance 
testing came under investigation and we observed that there are significant limitations associated 
with the sensitivity of the currently used proportion method. Our findings, together with those of 
others 6;10 suggest that the culture based method and critical drug concentration used for EMB 
testing needs to be critically re-examined. The reason for the low sensitivity observed in this 
study may include: - 1) The use of LJ slants instead of  plates may cause false susceptible 
results, as the colonies formed on the LJ slant will have the same color as the media making 
resistant detection difficult;  2) stability of the EMB in the test medium is important as EMB 
shows reduced activity in culture media as the drug is partially inactivated during media 
preparation 1;  3) the reading period after inoculation is vital as false susceptible results can be 
obtained if the reading time after inoculation is incorrect for that specific phenotypic test used18 ; 
4) the addition of Tween 80 can have an effect on susceptibility testing 1.  However, this is 
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unlikely since the phenotypic EMB results in BACTEC correlate with the genotypic findings in 
the study.   
In contrast to the indirect proportion method using solid media, we showed that the phenotypic 
BACTEC method (gold standard) correlated directly with the genotyping data.  The specificity 
and sensitivity of the genotyping method was 100 % and 97 % respectively when compared to 
the BACTEC method.  The primary limitations of the BACTEC culture based technique is that 
the results are available only after ± 30 days which further delays the implementation of 
appropriate therapy.   
 
The strong correlation between the BACTEC phenotype and the genotype methods implies that 
in this setting, mutations detected via PCR would be the appropriate method for rapid EMB 
resistance testing. As mutations conferring EMB resistance occur predominantly at one base in a 
single codon. We have developed a simple and robust multiplex PCR-ARMS method to rapidly 
identify isolates which are susceptible to EMB. This PCR amplification method generates two 
products; an internal control to confirm that the sample is amplifiable and a specific PCR 
product to demonstrate the presence of a “wild type” sequence at codon 306 in the embB gene. 
The inability to amplify the latter product strongly suggests a mutation at codon 306 and this 
implies resistance to EMB (provided the internal amplification control generates a specific 
product). Our results show that the method works extremely well, and has now been applied to 
directly amplify DNA from sputum specimens (data not shown). Further research is necessary to 
determine the cost-effectiveness of this technique. The method has certain limitations: 1) 
emerging EMB resistance will not be detected as the presence of the EMB sensitive strain’s 
“wild type” sequence will generate an amplification product, 2) isolates resistant to EMB via a 
mutation outside of the embB gene will not be detected.  However, such mutations account for 
less than 10% of EMB resistance 19. Despite these limitations, our results suggested that patients 
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infected with M. tuberculosis resistant to EMB will benefit from rapid diagnosis. The inability to 
accurately determine EMB susceptibility has consequences for both the patient and control 
program. Prolonged time delay between diagnosis of TB and the initiation of appropriate therapy 
may allow for the amplification of additional resistance markers. This in turn may prolong 
treatment, thereby placing unnecessary strain on the patient, increasing the risk of default and 
exacerbating the overall cost of treatment. Most importantly, diagnostic delay has the potential 
to increase the risk of transmission. The development of rapid molecular based drug 
susceptibility testing methods offers a rapid diagnosis and thereby could direct appropriate 
patient management within days of TB diagnosis. This is particularly important for the TB 
control program given the close (direct) association of EMB resistance with MDR-TB. 
 
 
CONCLUSION 
This study shows that there is a need to re-evaluate the routine phenotype susceptibility testing 
of EMB and suggests that genotypic detection of EMB resistance would do more  to enhance the 
management of MDR-TB cases. 
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The increase in drug resistant tuberculosis (TB) and especially multi-drug resistant tuberculosis 
(MDR-TB) is of concern. South Africa was listed in the third World Report on Drug Surveillance as 
one of the hot spots for MDR-TB, where more than 6000 new MDR-TB cases are detected each 
year (8). Recently, a bleaker picture has emerged with the discovery of extensively drug resistant 
tuberculosis (XDR-TB), an emerging threat for patients and control programs, since XDR-TB 
strains have developed resistance to first line and most second line drugs. 
 
Molecular methods such as strain genotyping (1,4) and drug resistance genotyping, have become 
valuable tools with which to study the epidemiology of drug resistant TB. These methods are also 
central to the identification and control of TB and MDR-TB in various areas around the world (7). 
The Beijing strain family is widely spread around the world and has been involved in many 
Chapter 5 
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outbreaks. It has been hypothesize that the Beijing family may have an enhanced propensity to 
transmit and cause disease (2,5,6).  
 
From February 2001 to December 2006, M. tuberculosis isolates from 1200 re-treatment cases from 
the Boland- Overberg-South Cape Karoo regions (BOKS) in the Western Cape South Africa were 
found to be drug resistant. Molecular analysis of these isolates (first isolate per case) showed that 67 
% of drug resistance in this region was driven by 4 strain families; Beijing (31 %), followed by X1 
(22 %), LAM3 (10 %) and the S family (4 %). Fig 1a shows that the proportion of drug resistant TB 
due to the Beijing strain family (n=375) increased steadily over time in relation to other drug 
resistant strain families (n=825). This suggests that the Beijing strain families may have enhanced 
fitness compared to the non-Beijing strain families. Additional, IS6110-RFLP analysis (1) of the 
Beijing strain family identified several drug resistant clones, of which cluster 220 is the largest 
(166/375; 45 %). After 2001, cluster 220 increased steadily (except for 2003 when sampling was 
low for an unknown reason) relative to other Beijing drug resistant strain clusters (Fig. 1b). These 
observations suggest that the transmission characteristics of M. tuberculosis strains are not 
conserved within strain families but rather that individual sub-lineages have unique transmission 
characteristics. The majority (63 %) of Beijing cluster 220 was phenotypically and genotypically 
resistant to INH and RIF (therefore MDR) and 36 % were resistant to INH only.   
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Thus far, no Beijing cluster 220 drug susceptible isolate has been identified in the region. More then 
90 % (n=151/166) of Beijing cluster 220 isolates have the inhA-15 (C-T) promoter mutation 
(conferring INH resistance) and 80 % had an identical rpoB 531TTG mutation (conferring RIF 
resistance) while 13 % of the RIF resistant isolates had other mutations (Table 1). These results 
imply that cluster 220 was initially fully drug susceptible, and then in a step-wise manner became 
resistant to INH followed by gaining additional resistance to RIF. The over-representation of 
Beijing cluster 220 in the whole geographical region strongly suggests sequential acquisition and 
amplification of resistance followed by recent spread in the community. It is possible that the inhA 
promoter mutation may have given cluster 220 a selective advantage to develop additional 
resistance and spread in the community. Geographical mapping indicated that the Beijing cluster 
220 drug resistant genotype is widespread in the BOKS region and was involved in a recent MDR 
outbreak in a high school in Cape Town (3). The result raises concern for the spread of drug 
resistant strains in vulnerable populations. Greater vigilance is required to contain the drug resistant 
TB epidemic in high prevalence settings. The emergence of this Beijing sub-lineage that shows 
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 Fig.  1a) Ratio of the Beijing drug resistant genotype in comparison to non-Beijing resistant genotypes.  
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increased transmissibility may have important implications for the tuberculosis Control Program 
and it is important that early diagnosis and contact tracing should be a top priority in order to curb 
the spread of this transmissible drug resistant strain. 
 
 
 
Table1. Beijing Cluster 220 Phenotype and Genotype 
  Phenotype Genotype 
  INH mono RIF MDR 
inhA-15 
prom rpoB531ttg 
other rpoB 
mut wt 
n=166 61 (36 %) 105 (64 %) 104 (63 %) 151 (91 %) 84 (80 %) 14 (13%) 7 (6 %)
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SUMMARY 
During October 2005, 4 children in a school in Cape Town were identified with MDR-TB. 
Genetic analysis confirmed that these isolates belonged to a single cluster (Beijing cluster 220) 
and all harboured a -15 inhAC-T promoter mutation demonstrating transmission. Genetic analysis 
of isolates cultured from patients from the Boland–Overberg-South Cape-Karoo and Cape Town 
regions showed that 28 % (58/209) of patients infected with a Beijing strain had the cluster 220 
genotypes and all harboured the same -15 inhAC-T promoter mutation. The presence of these 
transmissible MDR-TB strains may pose a threat to the community and rigorous infection 
control measures are needed to ensure the safety of those exposed.   
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INTRODUCTION 
During 2004, over 44 000 people were diagnosed with TB in the Western Cape Province of 
South Africa, of which 450-600 cases had multidrug resistant (MDR) TB 1. The TB epidemic in 
this area is primarily driven by four strain families with the Beijing strain family predominating 
amongst drug resistant strains 2. In this study we have used molecular methods to investigate the 
geographical distribution of a strain identified in a recent MDR-TB outbreak amongst children at 
a high school in Cape Town, South-Africa.  
 
 
MATERIALS and METHODS 
During October 2005, 4 adolescents from a school in Cape Town were identified by the TB 
control program with MDR-TB after not responding to first-line anti-TB treatment. DNA from 
the first culture from each case was extracted and typed by the IS6110–restriction fragment 
length polymorphism (RFLP) 3 method, spoligotyping 4 and DNA sequencing 5.  
 
In addition, we used a novel multiplex PCR method to rapidly detect the outbreak strain in a one 
step reaction, as describe below. Primers were designed according to the IS6110 junction (point 
of insertion: 954.19) Fig1a, unique to the Beijing cluster 220 strain type identified in the 4 
school cases. Each PCR reaction contained 1 μl DNA template, 5 μl Q-Buffer, 2.5 μl 10 x 
Buffer, 2 μl 25 mM MgCl2, 4 μl 10 mM dNTP’s, 0.5 μl of each primer (50 pmol/μl) (ESAT-6-
for 5’ cag cag cag tgg aat ttc gc 3”, ESAT-6-rev 5’ tcc cag tga cgt tgc ctt c 3, IS6110-xhoIfor 5’ 
ttc aac cat cgc cgc ctc tac 3’ and 954.19-rev 5’ aat cgt tga tgc tgg cgc tat gaa cc 3’) and 0.125 μl 
HotStarTaq DNA polymerase (Qiagen, Germany) made up to 25 μl with H20.  Amplification 
was initiated by incubation at 95 °C for 15 minutes, followed by 35 cycles at 94 °C for 1 minute, 
62 °C for 1 minute, and 72 °C for 1 minute. After the last cycle, the samples were incubated at 
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72°C for 10 minutes.  PCR amplification products were electrophoretically fractionated in 1.5 % 
agarose in 1 x TBE pH 8·3 at 6V/cm for 4 hours, and visualized by staining with ethidium 
bromide. A 270 bp PCR product indicated the presence of M. tuberculosis, while the 160 bp 
PCR product indicated the presence of the strain (Beijing cluster 220) (Fig.1). This PCR method 
is able to identify all 220 cluster isolates, and although it may also pick up 322 and 219, these 
occur very infrequently in our population.   
 
This PCR method was used to retrospectively screen archived Beijing isolates (n = 209 drug 
resistant, 100 drug susceptible Beijing genotypes), collected over a 4 year period between 
February 2001 and May 2004 from the Boland–Overberg-South Cape-Karoo (BOKS) 2 regions 
and from an epidemiological field site in metropolitan Cape Town 6 in the Western Cape 
Province South Africa. The set of samples included both new and re-treatment cases of infected 
Beijing isolates. This study was approved by the ethics committee (ethics approval 2002/C118) 
of Stellenbosch University, Tygerberg, South Africa and was done on request of the Provincial 
Health Department as part of an outbreak investigation and therefore individual written consent 
was not obtained from the parents of the children. 
 
 
RESULTS and DISCUSSION  
Spoligotyping showed that the 4 adolescents from one school were infected with Beijing strains. 
IS6110-RFLP typing confirmed that these isolates all had identical IS6110 hybridization bands 
(fig 1a) and belonged to the Beijing cluster 220. DNA sequencing showed that all 4 isolates had 
a -15 inhAC-T promoter mutation (conferring isoniazid resistance) and rpoB531TCG-TTG gene 
mutation (conferring rifampicin resistance). 
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1 (b)   
 
 
Figure 1: A. A representative IS6110-RFLP fingerprint of Beijing drug resistant cluster 220 genotype. B. PCR 
amplification of the Beijing cluster 220 genotype (lanes 1-4), M. tuberculosis Beijing cluster 208 (lane 5), 
H37Rv control (lane 6) and molecular marker (lane 8)  
 
 
These results confirmed that the isolates were identical and reflected recent transmission. The 
newly developed PCR-based method correctly identified the Beijing cluster 220 genotype (fig 
1b) from the 4 school children. Using this method, we found that 28% (58/209) of the archived 
M. tuberculosis Beijing drug resistant isolates had the Beijing cluster 220 genotype. All INH 
resistant Beijing cluster 220 genotypes from the BOKS and Cape Town regions had the same -
15 inhAC-T promoter mutation. Forty-four percent (25/58) of these isolates also had rpoB gene 
mutations (rpoB531 TCG-TTG, n=23; rpoB526 TCG-TAC, n=2) associated with rifampicin resistance 
and are thus MDR. A total of 100 drug susceptible isolates was screened for the -15 inhAC-T 
promoter mutation and to date, no Beijing cluster 220 drug susceptible isolates, harbouring that 
specific mutation, has been identified. Geographical mapping indicated that the Beijing cluster 
Point of IS6110 insertion 
XhoI
954.19 
      1(a) 
Beijing cluster 220 
260 bp 
160 bp 
 1        2       3       4       5       6       7                 8 
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220 drug resistant genotype is widespread in the Western Cape (fig 2). Most of the cases were 
found in the Worcester (n=18), Mosselbaai (n=11), George (n=9), Cape Town (n=10) and other 
areas (n=10) respectively (fig 2). Thirteen paediatric cases were also shown to be infected with 
the Beijing cluster 220 drug resistant genotype in a study conducted from March 2003 through 
August 2005 at Tygerberg Children’s Hospital, in the Western Cape Province (personal 
communication, Dr. Simon Schaaf). The results demonstrate that all 4 school children were 
infected with a Beijing cluster 220 MDR genotype which appears to be widely distributed in the 
Western Cape. Although a susceptible counterpart of Beijing cluster 220 has not been found, it is 
assumed that this strain was originally fully drug susceptible and acquired drug resistance by 
sequential selection (initially isoniazid, followed by rifampicin) and that the resistant progeny 
were then disseminated by transmission. The dominance of this Beijing drug resistant cluster 
220 genotype suggests that it may be more fit than other drug resistant clusters from the same 
Beijing strain family which were less frequently observed in local communities.   
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Fig 2. Clinic location where the cases presented with disease were used to construct a geographical map of Beijing 
cluster 220 genotypes.  The ratio of Beijing cluster 220 in relation with the total number of Beijing strains found in 
each location is indicated below. Cases with cluster 220 were distributed in large towns as follows: Worcester 
(n=18/45), Mossel Bay (n=11/18), George (n=9/25), Cape Town (n=10/71), Knysna (n=3/13), Villiersdorp (n=2/5), 
Caledon (n=2/2) and other areas (n=3/30 
 
Application of molecular methods such as were used in this study, have been central to the 
description and control of other MDR-TB outbreaks.7  Previous culture-based drug surveillance 
studies from the same region have failed to identify drug resistant outbreaks and suggested that 
drug resistance is largely acquired.8;9  The occurrence of this outbreak in a setting in which a 
direct observed therapy strategy (DOTS) programme was in place, testifies to the need to 
dedicate more resources to intensify the basic DOTS strategy as well as extend them to include 
Epidemiological 
Field site:  
Cape Town 
BOKS 
region 
2 of the 4 health districts in the Western 
Cape Province 
Worcester 
Villiersdorp 
Caledon Mossel Bay 
George 
Knysna 
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specific activities directed at the diagnosis and treatment of MDR-TB (DOTS Plus). The 
presence of these transmissible drug resistant strains poses a threat to healthcare workers and 
others in the community and suggests that rigorous infection control measures are needed to 
ensure the safety of those exposed to infectious sources with highly transmissible MDR-TB 
strains.   
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ABSTRACT 
Currently, isoniazid still forms an important part of the first line anti-tuberculosis therapy, but the 
molecular mechanisms conferring isoniazid resistance remains poorly defined. Currently there are 5 
genes known to be associated with isoniazid resistance an recently an additional 11 genes was 
identified by microarray analysis that might play a role in isoniazid resistance. The aim in this study 
was to quantify the expression level of genes, induced by INH, in a susceptible and resistant M. 
tuberculosis strain Beijing strain family. Two Beijing cluster 208 isogenic strains were selected 
from an existing strain bank and treated with sublethal concentrations of isoniazid. Quantitative 
real-time PCR analysis was performed on the 11 genes that were induced upon INH treatment. After 
5 hrs of exposure, most of the isoniazid induced genes in both the resistant and susceptible strain 
showed a low level of response to INH treatment except for accD6, acpM, efpA and Rv1772. After 
24 hrs of treatment most of the INH induced genes was found to be significantly regulated. Using 
this data we proposed a mechanism (based on the QRT-PCR results whereby drug resistant strains 
can compensate for the toxic effect of the drug. In addition we conclude that resistance in 
tuberculosis may be a combination of mutations in certain genes and their regulatory domains which 
regulate the intracellular concentration of the drug. 
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INTRODUCTION  
Soon after Isoniazid (INH) was introduced in 1952, INH resistant Mycobacterium tuberculosis (M. 
tuberculosis) strains were noted (2,4,13,14,18). Currently, INH still forms an important part of the 
first line anti-tuberculosis (anti-TB) therapy, but the molecular mechanisms of INH action and 
resistance remains poorly defined (11,12). It is proposed that INH enters the bacterium as a prodrug 
that is activated by catalase–peroxidase (CP), a product of the katG gene (7). Reduced or loss of CP 
activity due to gene mutations, or a whole katG gene deletion, is one of the primary mechanisms 
conferring resistance to INH (8). In addition, a further 4 genes ( inhA, kasA, ndh and ahpC) are 
associated with INH resistance (1,9). However, mutations in these 5 genes are absent in 25-30 % of 
INH resistant clinical isolates collected from various geographical regions (15,16). These results 
imply that other genes or mechanisms are involved in INH resistance (10).  
 
Studies using microarray technology have demonstrated additional genes that are induced in the 
bacterium after exposed to INH (3,5,17,18). Some of these genes encode for Type II fatty acid 
synthase (FAS-II) enzymes, which are important for mycolic acid biosynthesis. Other genes that are 
affected by INH and that mediate the toxic effect of the drug include acpM, kasA, kasB, fbpC; fadE, 
efpA, iniA, iniB, ahpC, accD6, Rv1592 and Rv1772. However, even though they fall within the INH 
pathway, none of these genes could thus far be directly linked to INH resistance by gene associated 
mutation.  
 
The aim in this study was to quantify the expression level of genes, induced by INH, in a 
susceptible and resistant M. tuberculosis strain Beijing strain family. 
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MATERIALS AND METHODS 
Strain selection  
Between February 2001 to December 2006, phenotypic drug resistant Beijing isolates (n=370) were 
selected from an existing strain bank containing, phenotypic, genotypic and demographical 
information, at the University of Stellenbosch. A minimum inhibitory concentration (MIC) of 0.1 
µg/ml of INH was considered susceptible and 1 µg/ml of INH was considered as moderately 
resistant whereas, 4 µg/ml of INH was considered highly resistant (6). Primers were designed for 
PCR amplification and DNA sequence analysis was done on all samples to identify mutations in the 
5 genes (katG, inhA, kasA, ndh and ahpC) known to be associated with INH resistance (Tables 1 
and 2). After screening of the 5 genes, no gene associated mutation could be identified in 30 % 
(118/370) of the Beijing drug resistant samples. IS6110-restriction fragment length polymorphism 
(IS6110-RFLP) analysis showed that the Beijing cluster 208 was the predominant cluster amongst 
these 118 samples. A subset of these 118 samples (phenotypically resistant, but no INH gene 
associated mutations) was then selected to screen for mutations in an additional 15 genes (as well as 
genes for which the promoters are known) whose gene expression was known to be influenced by 
INH exposure (18) (Tables 1 and 2). When no mutations could be identified after screening the 
additional 15 genes and their promoters, representatives of genetically isogenic (identical 
spoligotype, IS6110 RFLP pattern and DNA vs DNA microarray analysis (DNA vs DNA 
microarray data not shown) ) (Fig 1 and 2) Beijing cluster 208 strains was selected from those 
isolates. These strains included a Beijing fully susceptible (K636) and a INH mono resistant (R55) 
strain. A laboratory strain, H37Rv was used as a control. 
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Table 1. Genes analyzed to detect nucleotide sequence variations 
Gene Product and Function 
*KatG catalase-peroxidase 
*inhA Enoyl ACP reductase 
*inhA promoter  
*kasA β-Ketoacyl ACP synthase 
*ahpC Alkylhydroperoxidase 
*ndh NADH dehydrogenase 
•furA Ferric uptake regulator 
•mabA 3-Ketoacyl reductase 
•Rv0340 Unknown 
•iniB INH-inducible gene 
•iniA INH-inducible gene 
•iniC INH-inducible gene 
•srmR homolog regulatory gene 
•fabD Malonyl-CoA ACP transacylase 
•accD6 Acetyl-CoA carboxy;ase 
•fbpC trehalose dimycolyl transferase 
•fadE24 Fatty acyl-CoA dehydrogenase 
•nhoA Acrylamine N-acetyl transferase 
•efpA Efflux protein 
•Rv1592c Unknown 
•Rv1772 unknown 
* The 5 genes known to be involved in INH resistance (katG, inhA, kasA, ndh and ahpC) that were used to screen for 
mutations associated with INH resistance; • Fifteen genes known to be induced after exposure to INH (18). 
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Table 2. PCR primers and conditions used to amplify INH gene associated mutations  
 
 
 
Genes region Forward primers Reverse Primers Size (bp) 
Tm  
(°C) Reference 
katG 5' CAGAAACCACCACCGGAGCC '3 5' GCTGGTGATCGCGTCCTTAC '3 945 59 Current 
 5' TGGCCGCGGCGGTCGACATT '3 5' TCGGGGTCGTTGACCTCCCA '3 804 66 Current 
 5' CCGACGATGCTGGCCACTGA '3 5' GACCTCGACAAGCGCCCGCA'3 997 64 Current 
inhA prom 5' CGCAGCCAGGGCCTCGCTG '3 5' CTCCGGTAACCAGGACTGA '3 246 60 Current 
inhA 5' CACGTTACGCTCGTGGACAT '3 5' GGGTTCATGATCGGCAGGAG  '3 1300 64 Current 
kas operon 5' CTGAAAGCATCGACAGCAATG '3 5' GCA ACG CAA TCA CGT GTC TA 500 59 Current 
kasA 5' GTTCAGGCGAGGCTTGAG 3' 5' GCGATGTCGTGCTTCAGTAA '3 1293 50 (10) 
fabD 5' AAAAACATAGCTTACAGGCCCG '3 5' GTTGTGTACAAATCGAACTGACG '3 1071 59 (10) 
accD6 5' GACAGGAGACCTGCGATGAC '3 5' GGCAGAACAATCCGACCA '3 655 59 (10) 
 5' GGTTGGTCGGATTGTTC '3 5' CCTCGCGCGTGCGATTCTG '3 842 55 (10) 
ahpC prom 5' CGACTG GCTCATATCGAGAA '3 5' ATGAGAGCGGTGAGCTGGTA '3 411 49 (10) 
ahpC 5' GCTGATTGTCCGAGAGCATCG '3 5' GGTCGCGTAGGCAGTGCCCC '3 701 60 (10) 
 5' CCGATGAGAGCGGTGAGCTG '3 5' ACCACTGCTTTGCCGCCACC '3 236 66 (10) 
furA 5' GCGATCGGGTCCTAGCAG '3 5' TTCATATGACCCACGACGG '3 641 61 (10) 
ndh 5' ATCACCACCGCCGCTGAAGC 3' 5' GTTCGGGTACCCGGGAATG '3 1134 65 (10) 
 5' CATTCCCGGGTACCCGAAC '3 5' GTCGACCGTTTTGGCGTTGG '3 535 65 (10) 
mabA 5' CACGTTACGCTCGTGGACAT 5' AATCCGTTTGCCGTCCAGCA '3 500 60 (10) 
Rv0340 5' ATGCGTCGTATGCTTGG '3 5' CCAAACACCTATCGGGATC '3 850 54 (10) 
iniBAC prom 5' GAAATACCCGACACGACCAG '3 5' CCACCGATGAGATTTGGTG '3 450 59 Current 
iniB 5' ATAAGTTCCGGACCGGCG '3 5' CGACAGATGAGGCATAGCAG '3 1053 56 (10) 
iniB-iniA 5' TTGAACGGCGCTGCTATG '3 5' GTGCTGATGTCATCGACGG '3 1070 60 (10) 
iniA 5' CAACCGCAGCGGTTGACAT '3 5' CCGCATGCCGATAATCATT 3' 1079 61 (10) 
iniA-iniC 5' GGAATCGAAACCGCTGCG '3 5' CCAGCCCACCGATCTGTTTGA '3 1090 55 (10) 
iniC 5' TCCTGTTGCGCACCCTGAAC '3 5' AACATGTTCCACCCGGTGGC '3 1040 65 (10) 
srmR homolog 5' GCCAGTACCGGATCGACG '3 5'GTGTCGCGGACATCCTGG'3 819 63 (10) 
 5' CCAGGATGTCCGCGACACC '3 5'TGTCCGGGTGCGAGCAAC'3 835 67 (10) 
fbpC 5' GCATGGGTCTCTCCTCTG '3 5' GCTGATACCAGTCGGTGTAG '3 635 55 (10) 
 5' GCCAATCCAGTTTCTACACCG '3 5' ATGTTCCACACATCGGC '3 732 55 (10) 
fadE24 5' GCTATCAGATGCCTGGCG '3 5' GTGGGATCGAATAGTGGCTG '3 890 59 (10) 
nhoA 5' CTAGTGGCGCGAGCAGAC '3 5' CCGACGTCGACGAGATAGC '3 927 61 (10) 
 5' GCTATCTCGTCGACGTCG '3 5' GCATTCTACGTCTACGCCG '3 662 59 (10) 
efpA prom 5' GGGGCTATGAAGAAGTGCTG '3 5' GCTCTGAAGCGGTCTCCTC '3 500 59 Current 
efpA 5'ACCTCCCGCGATCATCG-3' 5' CGTCGAGCTTCATCCGTTC '3 810 59 (10) 
Rv1592 prom 5' AAAGAATTCGCGCTCTCAA '3 5' GTGGGAAGTAGAACGGATCG '3 450 59 Current 
Rv1592c 5' AACTCGGCGTACCCAACC '3 5' ACACGCTCGGAATTCAAGG '3 804 55 (10) 
 5' GAGCGTGTCGGGTTGTCC '3 5' CGAGGTTGTGTGCCAGGTC '3 834 55 (10) 
Rv 1772 prom 5' CCGAAGAGCGATGAGGATAC '3 5' TCATGTTTCCGATTGAGGTG '3 500 59 Current 
Rv1772 5' CGGGTGTTTCTCAACGAC '3 5' GGACTGGACTCGCTGATTG '3 633 55 (10) 
* All PCR reactions were run for 40 cycles and proceeded by a denaturation step at 95 °C for 15 min and included a final extension step at 72 °C for 10 min
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Fig 1. Spoligotype patterns and IS6110-RFLP profiles of strains investigated. A) Beijing K636 susceptible spoligotype, 
B) Beijing R55 resistant spoligotype C) RFLP-IS6110 profile of K636 Beijing cluster 208 susceptible strain  D) RFLP-
IS6110 profile of R55 Beijing cluster 208 resistant strain.   
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Fig 2. DNA vs DNA Microarray analysis: 2) DNA Microarary analysis was performed on genomic 
DNA obtained from the (drug susceptible strain (K636) vs the INH mono drug resistant strain (R55). 
No differences were identified, indicating that these two strains were isogenic (data not shown).  
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Culture and drug treatment 
The M. tuberculosis H37Rv, Beijing susceptible (K636) and resistant (R55) strains were grown on 
Löwenstein–Jensen (LJ) slants at 37 °C for three weeks with continuous aeration. One LJ was used 
to start an initial culture for subsequent RNA analysis. Ten milliliters 7H9 Middlebrook medium 
(Becton, Dickinson, Sparks, MD 21152, USA) (supplemented with 0.2 % (v/v) glycerol, 0.1 % 
Tween 80 and 10 % ADC) in vented screw-cap, tissue culture flasks (Greiner Bio-One, Maybach 
street, Germany) was incubated with colonies from the LJ slant at 37 °C (without shaking). After 10 
days, cultures were sub-cultured into 20 ml 7H9 Middlebrook media (supplemented with 0.2 % 
(v/v) glycerol, 0.1 % Tween 80 and 10 % ADC) and after 10-14 days of growth (0.7-0.8 OD600), 1 
ml aliquots were taken and stored at -80 °C. 
 
Two biological replicate experiments were performed (which included 2 biological and 2 technical 
replica experiments for each strain) in which a starter culture was set up by diluting an inoculum of 
the initial culture 1:100 into 80 ml fresh 7H9 media and incubating  at 37 °C without shaking until 
mid log phase (0.6-0.8 OD600). At this point the liquid culture was divided into two portions; INH 
was added to 40 ml of the culture, while the remaining 40 ml was untreated and served as the 
control. Drug treatment was done by adding filtered-sterilized stock solution of INH in water (INH 
was prepared as per manufacture’s instructions) (Becton Dickinson, Maryland 21152, USA) to 
achieve a final concentration of 0.1 µg/ml. Cultures were harvested by centrifugation after 
completion of the drug treatment periods of 5 hrs and 24 hrs. Similarly, the control liquid cultures 
that were not exposed to INH were harvested at 5 hrs and 24 hrs.  
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RNA isolation 
One hundred milliliter of a 5M guanidinium thiocyanate (GITC) (Sigma-Aldrich, St. Louis, USA) 
solution (5 M GTC, 0.5% sodium N-lauryl sarcosine, 0.1 M ß-mercaptoethanol, 12.5ml of a 1M 
sodium citrate pH 7.0 and 1% Tween 80 made up to 500 ml with RNase free water and filter 
sterilized) was added to each 2 x 20 ml culture. Bacteria were harvested by centrifugation (20 min. 
3000 x g, 19 °C) and the top aqueous layer was discarded. The pellet was resuspended in 1.5 ml 
Trizol (Life Technologes, Gaithersburg, MD). The trizol suspension was then transferred to a FAST 
Prep tube (Bio 101, Vista CA) and mechanically disrupted in a Ribolyzer (reciprocal shaker: 
Hybaid) for 45 sec at 6.5W for 2 cycles and cooled on ice for 1 minute between pulses. The samples 
were centrifuged at 13000 r.p.m. for 1 min in a microfuge and the trizol solution that is above the 
bed of beads was collected into a 2 ml phase lock gel tube (Eppendorf, Hamburg 22331, Germany) 
tube containing 300 µ1 of chloroform isoamyl alcohol (24:1 v/v) (Sigma-Aldrich,St. Louis, MO, 
USA). The tube was inverted several times before the aqueous layer was recovered by 
centrifugation (5 min, 13 000 r.p.m). The aqueous layer was transferred to a clean 1.5 ml eppendorf 
tube and the RNA was precipitated with the addition of an equal volume of isopropanol (Merck, 
Darmstadt, Germany). This was followed by incubation at -20 °C for 16 hrs. The crude RNA 
fraction was then pelleted (30 min, 13 000 r.p.m, 4°C) and washed with 1 ml 70 % ethanol (Merck, 
Darmstadt, Germany), air dried and re-dissolved to a final volume of 70 µl. Crude nucleic acid 
concentration was determined spectrophotometrically. Remaining traces of DNA were digested by 
treating 30 µg RNA with 6 units DNase I (Ambion) at 37 °C for 30 min. Followed by DNase I 
inactivation at 70°C for 10 min. The quality and concentration of the purified total RNA was 
analysed by gel electrophoresis, as well as by analysis using the Agilent 2100 Bio Analyzer (Agilent 
Technologies). 
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Quantitative Real-time -PCR (QRT-PCR)  
cDNA was synthesized from 1µg of purified RNA according to the manufacture’s instructions 
(Quantitect® Reverse Transcriptase kit (Southern Cross Biotechnologies)).  Primers for each gene of 
interest (Table 3) were designed using Primer software 3 version 0.2 (Whitehead Scientific). Light 
cycler Master mix was prepared by adding  1 µl of a 1:10 dilution of the cDNA, 1 µl of each primer 
pair (10 µM) (Table 3), 2 µl Light Cycler Faststart DNA Masterplus SYBR green Mix (Roche 
Diagnostics, Indianapolis,USA 0001) and RNase free water to a final volume of 20 µl. QRT-PCR 
was performed using a Lightcycler 2.0 system (Roche Diagnostics). A four step PCR parameter 
protocol was used: (i) denaturation program (95°C for 10min), amplification and quantification 
program repeated for 40 cycles (95 °C for 10 s, 59 °C for 10 s, 72 °C for 6s), (ii) melting curve 
program (95 °C for 0 s, 65 °C for 15 s, 95 °C with a heating rate of 0.1 °C/s) and a cooling down 
program of 40 °C for 30 s. The quantity of cDNA in each reaction was determined from the 
exponential phase of amplification from the cycle threshold (Ct). The transcriptional level of each 
candidate gene was quantified by using the delta-delta Ct calculation in which the relative 
abundance of mRNA of the target gene was normalized relative to the levels of the reference RNA 
transcripts (16S rRNA and ftsZ) and the control samples. Data analyses were done according to the 
delta-delta Ct equation R=2-(∆Ct sample-∆Ct control) and no efficiency correction are performed. 
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Table 3.  Primers used in QRT-PCR 
 
 
 
 
 
 
 
 
Gene Forward primer Reverse Primer 
Size 
(bp) 
Tm 
(°C) 
Reference 
kasA 5’CCGACCCTGAACTACGAGAC’3 5’AACCCGAACGAGTTGTTGAC‘3 100 60 Current 
ahpC 5’TCAGCAAGCTCAATGACGAG‘3 5’ATCGGGAAGGGTAACGTTTT‘3 120 60 Current 
iniA 5’GTCATGATTGGCATGCTGTC‘3 5’AGCAACCGGTTTTGTTTGTC‘3 120 60 Current 
iniB 5’GCTAGCCAGATCGGTGTCTC‘3 5’GCGTTGGAAGCCAACACT‘3 125 60 Current 
efpA 5’TAGGTTTCATCCCGTTCGTC‘3 5’CACGGTGCATGAAAAATGAG‘3 115 60 Current 
Rv1592 5’TCCGTTCTACTTCCCACCTG‘3 5’TACATGTTCGTGGTCCGGTA‘3 120 60 Current 
Rv1772 5’TGGGTTCAACAGGAGGTAGC‘3 5’CCGAAGAGCGATGAGGATAC‘3 120 60 Current 
fbpC 5’ATATCTGCAGGTGCCATCC‘3 5’ATGTCCCAGCCGTTGTAGTC‘3 120 60 Current 
fadE 5’AGCCAGCGACAACGACTATT‘3 5’TTCACATACGGGACGACGTA‘3 120 60 Current 
acpM 5’ AGGACAAGTACGGCGTCAAG’3 5’ GGGGTTCTCCGACTCAATCCT ‘3 120 60 Current 
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RESULTS 
QRT-PCR analysis was done on 11 genes previously shown to be up regulated when M. 
tuberculosis was exposed to 1 µg/ml of INH (18) (Table 4). QRT-PCR analysis showed the 
occurrence of significant changes (where a 5 fold increase/decrease in expression was defined as 
significant) on a transcriptional level of the selected genes in both resistant and susceptible strains 
after exposure to 0.1 µg/ml of INH for 5 hrs and 24 hrs (Table 5), respectively. After 5hrs of 
exposure, most of the INH induced genes in both the resistant and susceptible strain showed a low 
level of response except for accD6, acpM, efpA and Rv1772 that showed significant differences in 
expression between the susceptible and resistant strain. In comparison to the untreated INH control, 
it is interesting to note that accD6, acpM, Rv1772 and efpA were upregulated in the drug resistant 
strain (R55). In comparison, the transcript levels of accD6 and acpM were significantly up-
regulated in the drug susceptible strain (K636). A delayed response after 24 hrs of INH treatment 
was observed in which the following genes in the resistant strain (R55) was found to be 
significantly up-regulated in ahpC, kasA, iniA, iniB whereas fbpC was found to be down regulated. 
In the susceptible strain (K636) iniA, iniB and fbpC found to be significantly up-regulated after 24 
hrs while a down regulation was observed in the acpM gene. 
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Table 4. Gene differentially regulated after 1µg/ml of INH treatment (18). 
ORF Gene Product 
Rv3140 fadE23 probable acyl-coa dehydrogenase 
Rv2846c efpA possible integral membrane efflux protein 
Rv2428 ahpC alkyl hydroperoxide reductase c protein ahpc 
Rv2247 accD6 acetyl/propionyl-coa carboxylase 
Rv2245 kasA beta-ketoacyl-ACP synthase 
Rv2244 acpM Acyl carrier protein 
Rv1772 Rv1772 hypothetical protein 
Rv1592c Rv1592c conserved hypothetical protein 
Rv0342 iniA isoniazid inductible gene protein iniA 
Rv0341 iniB isoniazid inductible gene protein iniB 
Rv0129c fbpC Trehalose dimycolyl transferae 
 
 
Table 5. QRT-PCR gene expression profile of INH induced genes 
QRT-PCR 
Fold change 5hrs Fold change 24 hrs Genes 
#K636 $R 55 #K636 $R 55 
ahpC 2.3 2.5 2.7 10.77** 
kasA 2.7 2.8 1.3 23.3** 
accD6 11* 6.7* 15.6** 5* 
acpM 52* 4.9* 35.4** 5.6* 
iniA -2.7 1.5 2.3 10.2** 
iniB -2.9 1.6 4.4** 25.7** 
Rv1592 3.8 1.6 4.4 2.5 
Rv1772 1.7 6.2 2.9 7.7** 
fbpC 2.1 1.1 13.4** -7 
fadE 1.1 -1.1 -1.1 2.1 
efpA 2.6 12.5* 3.0 16.7** 
Legend 5: $Resistant strain (R55); #susceptible strain (K636); * genes that are upregulated in comparison to control after 5hrs; ** Significant up 
regulation of genes after 24hrs of treatment;  significant down regulated after 24hrs of INH.
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Fig 4. Response of INH induced genes in a Beijing cluster 208 resistant (R55) and susceptible (K636) strain as measured by QRT-
PCR analysis. Ratio of the cDNA copies detected in each sample relative to the time zero control by QRT-PCR at 5hrs and 24hrs
Beijing cluster 208 clinical strains response to 5hrs and 24hrs INH 
treatment measured by QRT-PCR
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Discussion 
This is the first report to describe gene expression in well characterized isogenic Beijing strains after 
exposure to low concentrations of INH which have a bacteriostatic effect on cell growth in pan 
susceptible strains. Previous reports on INH induced gene expression were based on studies 
performed on the laboratory strain H37Rv or other resistant clinical isolates after exposure to lethal 
concentrations of INH (3,5,6,17,18). These studies indicated that a number of genes were regulated 
after induction with INH. It was suggested that differences in observed gene expression levels could 
have resulted from either the different strains analyzed or the concentration of INH used. The genes 
identified are biochemically relevant to the drug’s mode of action, but their functional role in 
acquiring INH resistance in clinical isolates remains unclear. It is also not clear which modulators 
are involved in the regulation of these genes in certain strains, thereby conferring a resistant 
phenotype. It is specifically important to know which genes are regulated by low levels INH in 
resistant clinical isolates since it may provide novel insights into the mechanisms of resistance in 
clinical isolates where the classical mutations conferring resistance are absent. 
Genes that was differentially regulated included acyl-coA dehydrogenase (fadE) and Trehalose 
dimycolyl transferase (fbpC). Both of these genes play a role in mycolic acid biosynthesis which 
form an important part of the cell envelope and inhibition may lead to cell death. FadE is a 
negatively controlled gene that binds to transcription factors that regulate the expression of fatty 
acid biosynthesis. FbpC is an export protein that has a catalytic effect for the maturation of the 
mycolic acids in the cell wall. FbpC was found to be upreglated in the susceptible strain and down 
regulated in the resistant strain. Other genes identified include a efflux protein (efpA) that play an 
important role in drug tolerance as well as 2 isoniazid inducible gene called iniA and iniB. The” ini” 
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genes encode transmembrane proteins that act through pump like mechanisms to actively pump the 
drug out of the cell, resulting in increase resistance to INH. The kasA genomic region consists of 5 
genes in an operon (fabD, acpM, kasA, kasB and accd6). All of these encode for enzymes that is 
involved in the fatty acid biosynthesis pathway. It has previously been shown that these genes are 
differentially regulated in M. tuberculosis in the presence of activated INH. Rv 1592 and Rv1772 are 
conserved hypothetical proteins of unknown function. It is likely that these hypothetical proteins 
may play important roles in the cellular homeostatis of the cell and further studies are required to 
define their role in M. tuberculosis. Thus, the possibility exists that the expression of these genes 
activates certain pathways, which could be linked to INH resistance. 
In this study, we selected a list of candidate genes which have been previously described to be 
regulated when H37Rv was exposed to 1 µg/ml of INH (18). These include genes from part of the 
FASII complex, which are important in the pathway for the synthesis of mycolic acids. However, 
the precise mechanism of action of some of the genes remains unresolved. According to our QRT-
PCR results (Table 5, Figure 4 and 5) and current opinion, it is suggested that in a susceptible strain, 
INH enters the bacterial cell as a prodrug and is activated by catalase peroxidase produced by KatG. 
Activated INH then binds to the NADH in the pocket of the enoyl-acyl carrier reductase (InhA), by 
forming a covalent complex between the KasA-AcpM proteins. As a result of this activated INH, 
mature mycolates are not produced. This accumulation of mycolates is then sensed by the KasA-
AcpM resulting in an increase in the expression of AcpM (Fig 5). A increase in the expression of 
fbpC, one of several exported proteins, was observed. We proposed that fbpC is upregulated due to 
the accumulation of mycolic acid. As a result can no mature mycolates be transferred to the cell 
wall, and thus rendering the bacterium susceptible to INH which then result in cell death. 
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According to our QRT-PCR results (Table 5, Figure 4) we propose (Figure 5) that in a resistant 
strain (in the absence of any gene mutation), INH enters the cell and is activated by catalase 
peroxidase. KatG on its own is not sufficient to detoxify H2O2, and this imbalance is sensed by the 
organism resulting in an increase in the synthesis of AhpC. This delayed AhpC response assists with 
the detoxification of the reactive oxygen species from the bacterial cell, as well as the possible 
inactivation of INH. This activated INH is then sensed by the efpA gene resulting in an up-
regulation of expression and as a result INH is actively pumped out of the cell. A delayed increase 
in expression of iniA and iniB genes was also observed, suggesting that these proteins may assist in 
the action of EfpA to detoxify the cell. Down regulation of fbpC was observed implying that mature 
mycolates was formed and exported to the cell wall assisting in the efflux of INH from the cell. A 
increase in accD6 and Rv1772 activity was also observed, however, the role of these proteins in the 
INH metabolic pathway remains unclear.  
 
We therefore conclude that drug resistance in tuberculosis may be a combination of mutations in 
certain genes and their regulatory domains which regulate the intracellular concentration of the 
drug. However, these mutations remain to be determined. The application of whole genome 
sequencing of these two strains could provide novel insights into the mechanisms used by this strain 
to evade the toxic effect of INH. 
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Fig 5. There hypothesize mechanism of INH action in susceptible and resistant strain with respect to 
results obtained by QRT-PCR 
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ABSTRACT 
Isoniazid is a front line anti-tuberculosis drug. However, about 26 % of isoniazid resistant Beijing 
clone 208 phenotype lack a known gene associated mutation. Thus, the aim of this study was to 
make use of proteomics in order to identify any protein that might play a role in isoniazid resistance. 
A Beijing cluster 208 fully drug susceptible and a isoniazid mono resistant (with no gene associated 
mutations) was selected from a existing strain bank for protein analysis. Both strains were grown to 
mid log phase after which it was exposed to 0.1 µg/ml of isoniazid. Cultures were harvested upon 
completion of drug treatment of 5 hrs and 24 hrs. Differentially expressed protein spots were 
excised from the gel and used for subsequent Q-TOF analysis. Protein differences identified 
between Beijing resistant and susceptible M. tuberculosis strains irrespective of drug treatment 
included; major membrane protein, Rv3418c (GroES), and Rv3875 (Esat6). Expression differences 
observed after isoniazid treatment for the Beijing cluster 208 strain included two hypothetical 
proteins; Rv3678 and Rv2626c as well as a Rv1980c and Rv2428. Proteins identified were stress 
induced proteins, thus we hypothesize that the response observed in this study might not be due to 
the toxic effect of the drug, but rather reflect an isoniazid induced stress response. 
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INTRODUCTION  
The increase in the incidence of drug resistance has stimulated interest in understanding the 
molecular mechanisms of drug resistant tuberculosis. Completion of the Mycobacterium 
tuberculosis (M. tuberculosis) whole genome sequence (8) has enabled the annotation of 3998 
genes, which serves as a frame-work to understand how their encoded proteins could aid in the 
understanding of the development of drug resistance (23). Conventional proteomics relies on high-
resolution two-dimensional (2D) gel electrophoresis, mass spectrometry (MS) and database 
searching for protein identification. MS analysis entails the ionization of unknown proteins using 
matrix assisted laser adsorption ionization (Maldi) (1). Following ionization, the mass of the 
peptides is determined using, for example, quadrupole-time of flight (Q-TOF) analysis. These 
peptide masses can then be compared to a database to identify the protein. 
 
Researchers are currently striving to obtain a more complete understanding of the tuberculosis (TB) 
proteome and how it is influenced by current anti-TB drugs. Bacteria develop resistance to an 
antibiotic through spontaneous mutation and antibiotic selection. In the selective environment (in 
the presence of a drug), the sensitive bacterial population is killed and the resistant mutants are 
allowed to grow. This type of resistance is called acquired resistance and is defined by mutations in 
specific genes (16).  
 
Isoniazid (INH) is a first line anti-TB drug and has been in use since 1952. The manner in which 
INH kills M. tuberculosis remains unclear. However, it has been hypothesized that M. tuberculosis 
develops resistance to INH through mutations in genes (katG, inhA, ndh, ahpC and kasA) or their 
promoters. These mutations result in blocking the INH from binding to its targets (18,21). However, 
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mutations in these genes account for only about 70 % of INH resistance (9,16). Thus, approximately 
30 % of clinical isolates are phenotypically resistant to INH and do not have mutations in these 
genes (9,16). This implies that other, as yet unknown mechanisms (or genes), are involved in INH 
resistance.  
 
Molecular epidemiological studies have suggested that M. tuberculosis strains with the Beijing 
genotype have a higher propensity to acquire drug resistance (12). In this study setting the Beijing 
strain family is the most prevalent (31 %) drug resistant strain family (Chapter 5) and a quarter of 
these strains have an INH resistant phenotype in the absence of classical mutations. Thus the aim of 
this study is to determine what effect a bacteriostatic concentration of INH has on the proteome in 
order to identify proteins which may be up-regulated and thereby confer a INH resistant phenotype. 
 
 
MATERIALS AND METHODS: 
Setting up initial culture and M. tuberculosis growth rates 
An H37Rv, M. tuberculosis Beijing cluster 208 fully susceptible (K636) and INH mono-resistant 
strain (R55) were selected from an existing strain bank at the University of Stellenbosch. An initial 
culture was set up by scraping colonies from a Lowenstein-Jensen (LJ) slant, and then inoculated 
into 10 ml 7H9 Middlebrook medium (supplemented with 0.2 % (v/v) glycerol, 0.1 % Tween 80 
and 10 % albumin-dextrose-catalase (ADC)) in vented screw-cap, tissue culture flasks (Greiner Bio-
One, Maybach street, Germany). The culture was incubated without shaking at 37 °C. After 10 days 
the cultures were sub-cultured into 20 ml supplemented 7H9 Middlebrook media and after a further 
10-14 days of growth (0.7-0.8 OD600) at 37 °C, 1ml aliquots were stored at -20 °C.  
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Drug treatment 
A starter culture was set up by inoculating 0.8 ml freezer stock into 80 ml fresh supplemented 7H9 
media (1:100) and incubating at 37 °C (without no shaking) until mid log phase (0.6-0.8 OD600). 
Thereafter, the culture was divided into two; 40 ml of the culture served as control and the 
remaining 40 ml was incubated in the presence of INH (dissolved in H2O) (Becton Dickinson, 
Maryland 21152, USA) at a final concentration of 0.1 µg/ml at 37 °C for 24 hrs. After incubation at 
37 °C, the M. tuberculosis bacilli from each culture (cultured in the absence or presence of INH) 
were harvested by centrifugation (3000 g, 20 min). 
 
Whole cell lysate protein isolation 
Mycobacterial pellets were washed twice with 1 ml Phosphate buffer saline (pH7.4) containing 1 % 
(v/v) Tween-20 and centrifuged (13 000 rpm, 10 min). An equal volume (pellet volume) of silica 
beads (Bio 101,Vista,USA) and 200-500 µl lysis buffer (0·3 % (w/v) SDS, 200mM DTT, 50 mM 
Tris/HCl pH 7.0, 1 mM phenylmethanesulfonyl (Sigma-Aldrich, Germany) and complete protease 
inhibitor cocktail (Roche Molecular Biochemicals)) were added to the pellet and mixed by vortexing 
for 60 seconds. The cell suspension was then incubated at 80 °C for 20 min to inactivate the bacilli, 
after which it was rybolized (Bio 101, Vista, USA) for 45 seconds at 6.5 W for 2 cycles, with 
cooling on ice between pulses. The samples were incubated at 100 °C for 10 min after which they 
were centrifuged (13 000 rpm, 10 min) and the supernatant transferred to a clean 1.5 ml eppendorf 
tube. Protein concentration were determined according to the Bradford Assay (5).  
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2D gel electrophoresis. 
2D gel electrophoresis was performed as described previously by Betts et al (2), with minor 
changes. Briefly; approximately 50 µg of total protein was resuspended in rehydration buffer (8M 
urea, 2 % CHAPS, 10mM DTT, 2 % Pharmalyte and a trace of bromophenol blue) and made, up to 
a final volume of 200 µl, applied to a pH 4-7 isoelectrical focusing (IEF) strip for 20 hrs. IEF was 
performed under the following conditions; 100 V for 2 h, 300 V for 2 hrs, 1000 V for 1 hr and 3500 
V for 20 hrs. After IEF focusing, strips were stored at -80 °C. Second dimension electrophoresis 
was done by placing the equilibrated IEF strips onto a 12 % PAGE 
(http://www.expasy.ch/ch2d/protocols/) and sealing it with agarose (Bio-Rad Laboratories, 
Hercules, CA 94547). Gels were stained with silver stain compatible with mass spectrometry 
(http://www.expasy.ch/ch2d/protocols/) (4). Gels were scanned and recorded using a GS-800 
Calibrated Densitometer (Biorad) and quantitative spot detection and matching was visually. When 
protein spot differences were noted, gels were rerun, stained with a silver stain compatible with MS 
(4) and the spots of interest were excised from the gel.  
 
Scoring of differentially expressed protein spots 
Spot differentiation was visually recorded at least three times in three separate experiments. Spot 
differences for the quadruplicate gels were scored as follows : a protein spot was graded from + to 
+++, where + indicated the presence of a spot, ++ and +++ indicated an increase in spot intensity. 
The absence of a protein spot was indicated by a “-“. 
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Sample preparation for Q-TOF analysis 
The excised gel spots were placed in 50 µl of double distilled MilliQ H2O and sent to Imperial 
College in London where they were analyzed by Q-TOF analysis. Peptide sequence data generated 
at Imperial College was then searched against the non-redundant protein MASCOT database 
(http://www.matrixscience.com) to identify the protein of interest. 
 
 
RESULTS 
Fig 1 shows the electrophoretic fractionation of whole cell lysate (WCL) proteins in a 2D silver-
stained gel (pI range of pH 4-7 with a molecular weight of 10-66 kDa) that reveals approximately 
300 distinct protein spots.   
Comparison of protein expression between the susceptible and resistant strain (irrespective of drug 
treatment) showed 7 differentially expressed protein spots (Table. 1, Fig 1 and 2A). Only 5 of the 7 
protein spots could be structurally and functionally identified by Q-TOF analysis. Three of the 5 
protein spots had peptides that matched the annotated genome sequence; the remaining 2 protein 
spots were isoforms. The major membrane protein (MMP) showed increased expression in the 
susceptible strain relative to the resistant strain. The protein spot identified as ESAT-6 was found to 
be more dominant in the susceptible strain compared to the resistant strain. Different isoforms of the 
GroES protein were identified and variation in spots between the different isoforms was observed. 
For example, in one protein spot, the protein GroES was found in abundance in the resistant strain 
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(+++) compared to the susceptible strain (+), while in another protein spot with the same matched 
peptides (GroES), the protein was found in abundance in the susceptible strain (++) compared to the 
resistant strain (+).  
Comparison between the INH untreated control and 24 hrs INH treated cultures revealed 7 
differentially expressed proteins (Table 2, Fig 1 and 2B) of which 5 protein spots could be 
structurally and functionally identified by Q-TOF analysis in both susceptible and resistant cultures. 
Four of the 5 protein spots had peptide sequence that matched the annotated genome sequence; the 
remaining protein spot was an isoform (Table 2). The identified and the relative expression levels 
for each protein are shown in Table 2. Two of the protein spots encoded for hypothetical proteins 
(Rv3678 and Rv2626c) while the other three remaining protein spots encoded for ORF with known 
functions: i) different isoforms of alkyl-hydroperoxide reductase (Rv2428, AhpC) and ii) an 
immunogenic protein (Rv1980c, Mpt64)). In both resistant and susceptible strains an increase in the 
expression of the AhpC protein was observed. The Mpt64 protein was found to be down regulated 
in both resistant and susceptible strains.  
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Table. 1 Protein differences observed between Beijing Resistant (R55) and Beijing Susceptible (K636) M. tuberculosis isolates 
irrespective of drug treatment 
Spot ORF Protein Function Matched Peptide MW (kDa) pI Resistant Susceptible 
8 No. ID      + - 
9 Unknown Rv number MMP 
Major membrane 
protein, belongs to 
alpha-crystallin HspS, 
Family of small stress 
induce proteins 
(R)SEFAYGSFVR(T) 
(R)TVSLPVGADEDDIKATYDK(G) 19 5.9 + +++ 
10 Unknown Rv number MMP 
Major membrane 
protein, belongs to 
alpha-crystallin HspS, 
Family of small stress 
induce proteins 
(R)SEFAYGSFVR(T) 
(R)DGQLTIKAER(T) 19 5 + ++ 
11 No. ID      + +++ 
12 Rv3418c groES Chaperonin-10 
R)DVLAVVSK(-) 
(K)EKPQEGTVVAVGPGR(W) 
(K)RIPLDVSEGDTVIYSK(Y) 
10 4.6 +++ + 
13 Rv3418c groES Chaperonin-10 (R)DVLAVVSK(-) (K)EKPQEGTVVAVGPGR(W) 10 4.6 + ++ 
14 Rv3875 Esat6 
Early secretory Ag 
target, important for 
virulence 
(-)TEQQWNFAGIEAAASAIQGNVTSIHSLTK(L) 6 4.5 + ++ 
*Relative expression levels was graded from a “+” to a “+++”.  Protein spots absent are indicated by “-“.
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Fig 1. Two-dimensional electrophoresis patterns of M. tuberculosis Beijing Cluster 208: A) INH mono resistant isolate (no INH exposure) B) 
INH mono resistant isolates (treated with 0.1µg/ml INH for 24 hrs) (C) Susceptible isolate control (no INH exposure); D) Susceptible isolate 
(treated with 0.1µg/ml INH for 24 hrs) 
pI 4                                                                                    7 pI 4                                                                                    7 
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Fig 2. Protein expression differences between Beijing cluster 208 Clinical strains. 
A) Expression differences observed between Beijing INH mono resistant and drug 
susceptible clinical strains irrespective of drug treatment. B) Expression differences 
of Beijing clinical strain between INH untreated control and INH drug treatment. 
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Table. 2 Protein differences between Beijing cluster 208 control (no drug added) and 24hrs INH (0.1µg/ml) treatment for both 
susceptible (K636) and resistant (R55) isolates 
*Relative expression levels were graded from a “+” to a “+++”.  Protein spots absent are indicated by “-“ 
       Resistant (R55) 
Susceptible 
(K636) 
Spot ORF Protein Function Matched Peptide MW (kDa) pI Control 24hrs Control 24hrs 
1 No. ID      + +++ + + 
2 Rv3678 Hypothetical protein unknown 
(R)TGNLVYTAGQLPLEAGKLVR(T)  
(R)LGQLGVTLPQVAAPLAAYVPAVR(T) 
(K)VVGFVASAPGFHGQPSVINGASDLLAEVFGDSGAHAR(S) 
15 5.1 + - + - 
3 Rv2626c Hypothetical protein unknown 
(R)HLPEHAIVQFVK(A) 
(K)GLAAGLDPNTATAGELAR(D)   +++ - +++ + 
4 No. ID      ++ + ++ + 
5 Rv1980c Mpt 64 Immunogenic protein 
(R)GTQAVVLK(V) 
(K)FLSAATSSTPR(E) 
(K)SLENYIAQTR(D) 
(R)DKFLSAATSSTPR(E) 
(K)VYQNAGGTHPTTTYK(A) 
24 4.8 +++ + ++ + 
6 Rv2428 AhpC Alkyl hyroperoxidaseC (K)DFTFVCPTEIAAFSK(L) 21 4.5 + +++ + ++ 
7 RV2428 AhpC Alkyl hyroperoxidaseC 
(R)VVFFWPK(D) 
(R)ELSQAAGVLNADGVADR(V) 
(K)DFTFVCPTEIAAFSK(L) 
(K)PLLTIGDQFPAYQLTALIGGDLSK(V) 
(K)PLLTIGDQFPAYQLTALIGGDLSKVDAK(Q) 
21 4.5 + +++ + ++ 
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DISCUSSION 
In this study, the proteome of a drug resistant and drug susceptible Beijing strain that is dominant in 
the local community was analyzed to identify differences in expressed proteins after isoniazid 
exposure. Similar studies but with different experimental approaches, were performed previously 
(3,11,14,15,19,20). These studies differ with respect to strain type (H37Rv or a clinical strain other 
than Beijing), growth conditions (early log phase or late log phase cultures or cultures grown under 
O2 limitation) and the growth medium used (Sautons medium). Most of the proteins identified in 
these studies encoded for proteins of either known functional or hypothetical proteins. 
When the proteome of the INH induced strains was analyzed, no differences in protein spot 
intensity could be seen for any of the 5 known proteins (except for AhpC) involved in INH 
resistance or the additional proteins encoded by the 11 genes thought to be involved in the INH 
pathway. Previous reports using a early log phase H37Rv culture exposed to 0.1 µg/ml INH showed 
that 3 proteins (AhpC, KasA and the AcpM) were up-regulated in response to INH (14). The 
absence of induced proteins thought to be up-regulated by INH could be explained by: i) the 
translational response of INH in this study was measured by analyzing WCL proteins and a more 
selective group of INH induced proteins might have been observed if the proteins were fractionated 
prior to analysis and ii) INH induced proteins responsible for conferring INH resistance fall outside 
of the pI window of 4-7 with a molecular weight below 30 kDa, iii) high molecular weight proteins 
may not enter the gel and iv) low levels of INH might not significantly induce a translational 
response .  
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Comparison of the Beijing resistant strain to the susceptible strain revealed different isoforms of the 
MMP. The MMP forms part of the α crystalline (Acr) homolog and consists of a family of small 
stress-induced proteins (HspS). Acr is a M. tuberculosis membrane virulence factor that was found 
to be more dominant in the susceptible Beijing strain in comparison to the Beijing resistant strain. 
The Esat 6 protein which plays an important role in virulence was also found to be unregulated in 
the susceptible strain compared to the resistant strain. These observations are in concordance with 
the central dogma in which it is believed that susceptible strains are more virulent than drug 
resistant strains.  GroES is a molecular chaperone that cooperates with GroEL during protein 
folding. These two chaperonins are constitutively express and enhance synthesis of these proteins 
occur when the bacterium are put under stress. Different isoforms as well as different levels of 
expression of the same isoform was observed for this protein. We proposed that this phenomenon 
can be due to the different isoforms present during different stages of protein folding (10).  
One of the proteins induced by INH treatment was AhpC, a member of a large family of 
peroxidases, which is responsible for the antioxidant defense in bacteria (13). Up-regulation of this 
protein enables the bacterium to evade the toxic effect of INH and in this manner ensures to the 
bacterium’s intracellular survival. In mycobacteria, AhpC not only detoxifies H2O2 but also affords 
protection to cells against oxidative stress exerted by the host immune response (6,7,17). An 
immunogenic protein Mpt64 was also identified and found to be down regulated. Mpt64 induces 
strong delayed type hypersensitivity response. Up-regulation of AhpC and down-regulation of 
Mpt64 protein after INH treatment was consistent with previous reports (14,22). Different 
isoforms/mobility variants of the AhpC protein and that of the MMP protein could be due to 
posttranslational modifications.  
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We hypothesise that the response observed in this study might not be due to the toxic effect that 
INH has on the bacterium, but rather reflects an INH induced stress response. This observation is 
based on the fact that the protein spots were up-regulated in both the resistant and susceptible 
Beijing strains, irrespective of drug treatment.  
Based on these observations, we conclude that by using this strategy we were unable to identify new 
proteins conferring INH resistance as bacteriostatic concentrations of INH does not induce many 
changes within the proteome of M. tuberculosis Beijing cluster 208. 
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Conclusion 
Despite the implementation of the direct observed therapy strategy (DOTS) by the World Health 
Organization, TB still remains a public health problem in many countries. In South Africa, most of 
the patients infected with M. tuberculosis live in poverty under conditions that promote the spread 
of this infectious disease. Patients diagnosed with an M. tuberculosis infection are immediately 
treated with a 4 anti-TB drug regimen which includes; INH, RIF, EMB and PZA. Drug 
susceptibility testing (DST) is only done on patients who have previously been treated for TB and 
on patients who do not respond to two months of therapy. Accurate DST is essential to ensure that 
the patient receives the most appropriate treatment.  
 
Application of new molecular methods during the past two decades has significantly enhanced our 
knowledge of TB. Mutations in genomic targets of the drugs have been identified as the major 
mechanism of drug resistance. In the second theme of this thesis, we have made use of molecular 
techniques to rapidly identify patients infected with drug resistant strains. We found that more then 
90 % of EMB resistance has been missed by the culture procedure used in the routine TB laboratory 
and that 87 % of these patients were MDR. These results indicate that the inability of culture based 
techniques to accurately detect EMB resistance could significantly influence the treatment of such 
MDR cases. Currently, EMB is used as a second-line drug if the M. tuberculosis strain is sensitive 
to EMB. Failure to detect EMB resistance will result in inappropriate therapy which may result in 
prolonged treatment.  
Chapter 9 
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We have successfully detected resistance to INH, RIF and EMB from a 5 day mini culture by using 
molecular methods. In a comprehensive study, we found that genotypic results from all the samples 
tested were available in a significantly shorter time interval than the routine culture method. 
Furthermore, we were able to detect drug resistant–TB in samples which had lost viability (DST by 
culture cannot be done on these samples) circumventing the need to request follow-up sputum from 
patients in rural clinics. We proposed a protocol which can assist the control program for fast and 
accurate detection of drug resistance. In order to stop the spread of drug resistant strains, rapid tests 
must be introduced into routine laboratories. The TB control program has been informed about our 
findings and is currently in the progress to further evaluate molecular testing on a larger scale in 
South Africa. 
 
Molecular epidemiological studies have demonstrated the world wide occurrence of the Beijing 
genotype, thereby suggesting that this genotype has evolved unique properties. This genotype is 
currently one of the most well studied M. tuberculosis strain families globally. In the third theme of 
this study, we showed that more than 60 % of drug resistant TB is due to ongoing transmission of an 
already drug resistant strain. We also observed that strains with the Beijing genotype are the most 
dominant (successful) drug resistant strains in our study community. The result shows that the 
proportion of cases infected with strains with the Beijing genotype has increased over time. 
Furthermore, we found that a specific drug resistant Beijing strain (cluster 220) has a higher 
propensity to transmit and cause disease as compared to other drug resistant Beijing strains. The 
high frequency of the Beijing cluster 220 strain raises concern for the spread of drug resistant TB in 
vulnerable populations. This enhances the possibility of outbreaks of MDR TB, such as were 
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identified in a high school in Cape Town, South Africa. We recommend that greater vigilance is 
required to contain this drug resistant Beijing lineage (and other outbreak drug resistant strains) and 
that molecular detection should be central in the control program for the detection of these outbreak 
strains. This can be achieved by the development and implementation of rapid diagnostics, ensuring 
treatment adherence and intensify the screening of contacts. 
 
Many studies, including our study, have identified a subset of INH resistant clinical isolates without 
known drug resistance causing gene mutations. By using a transcriptional and translational 
approached (theme 4), we found several genes that are differentially expressed/translated between 
clinical isolates with different INH resistance phenotypes.  
 
In this study, we proposed a mechanism by which genes induced by INH (efpA, acpM, iniA and 
iniB) in a resistant strain, with no gene associated mutation, might be able to compensate for the 
toxic effect of the drug. The results also suggest that the susceptible bacterium sense a different 
response where the final execution step is the inhibition of mycolic acid.  
 
When the transcriptomics and proteomics result was compared, no overlap (except for the 
identification of the ahpC protein) was found between the two techniques. The level of a given 
mRNA is not positively correlated with the expression of the associated protein due to the 
occurrence of post transcriptional and post translation modification that might take place as well as 
the turn around time of mRNA into protein. QRT-PCR was used to validate the expression levels of 
the previously INH induced genes.  
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We come to the conclusion that treatment of drug resistant TB patients with standard concentrations 
of INH may be sub-optimal as the bacteria have other mechanisms of coping with low 
concentrations of INH. This must be particularly important in patients which are not compliant to 
anti-TB treatment. The genome of M. tuberculosis encodes several efflux putative proteins. Little is 
known about the role of these proteins in the regulation of drug resistance in M. tuberculosis. It is 
also possible that subtle changes in regulons that regulate gene expression may play a role in drug 
resistance. In order to fully understand the complete mechanism of resistance to INH, we propose 
that future studies should include whole genome sequence analysis.  
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